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ABSTRACT OF DISSERTATION

DEVELOPMENT AND APPLICATION OF GADOLINIUM FREE CARDIAC
MAGNETIC RESONANCE FIBROSIS IMAGING FOR MULTISCALE STUDY OF
HEART FAILURE IN PATIENTS WITH END STAGE RENAL DISEASE
Cardiac magnetic resonance (CMR) is a powerful tool to noninvasively
image ventricular fibrosis. Late gadolinium enhancement (LGE) CMR identifies
focal and, with T1 mapping, diffuse fibrosis. Despite prevalent cardiac fibrosis
and heart failure, patients with end stage renal disease (ESRD) are excluded
from LGE. Absence of a suitable diagnostic has limited the understanding of
heart failure and obstructed development of therapies in the setting of ESRD. A
quantitative, gadolinium free fibrosis detection method could overcome this
critical barrier, propelling the advancement of diagnostic, monitoring, and therapy
options. This project describes the development of a gadolinium free CMR
technique and application for cardiac fibrosis measurement in patients with
ESRD.
Magnetization transfer (MT) occurs during standard cine balanced steady
state free precession (bSSFP) CMR, where extracellular matrix protons
exchange magnetization with water molecules. Extracellular water volume
expansion, concomitant with fibrosis, reduces MT and subtly elevates signal
intensity. Our technique, 2-pt bSSFP, extracts endogenous contrast sensitive to
tissue fibrosis by obtaining pairs of high and low MT-weighted images and
calculating normalized signal differences, denoted by ΔS/So.
We tested 2-pt bSSFP in patients referred for CMR and found excellent
agreement spatially with LGE and quantitatively with extracellular volume
fraction. Diagnostic and clinical application of 2-pt bSSFP was comparable to
LGE. We applied 2-pt bSSFP to patients with ESRD for multiscale comparison
with correlates of fibrosis ranging from blood biomarkers to whole organ function.
Patients with ESRD displayed hypertrophy with reduced contraction, but elevated
ΔS/So and fibrosis. Some biomarkers correlated with both hypertrophy and
fibrosis, highlighting the need to distinguish between hypertrophic and fibrotic
remodeling. We monitored fibrosis over 1 year using 2-pt bSSFP in a cohort of

patients with ESRD. ΔS/So and fibrotic burden increased substantially, despite
minor changes in structure and function.
Collectively these studies validate and apply 2-pt bSSFP for gadolinium
free fibrosis CMR in patients with ESRD. While ventricular structure and function
are commensurate with progression toward heart failure, it is now possible to
specifically describe global and focal patterns of cardiac fibrosis in ESRD, along
with comparisons to blood biomarkers which may lead to improved diagnostics
and molecular treatment targets.
KEYWORDS: Cardiac Fibrosis, Magnetic Resonance Imaging, End Stage Renal
Disease, Hemodialysis
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CHAPTER 1: INTRODUCTION

Heart Failure
Epidemiology, Etiology, and Clinical Presentation
Heart disease is currently the leading cause of death in the United States
[1]. The prevalence of heart failure remains high at over 5.5 million adults in the
United States [2]. Over $20 billion in medical expenses are attributed to heart
failure. By the year 2030, the projected prevalence of heart failure is expected to
exceed 8 million Americans costing over $53 billion [3]. This is driven by both the
increasing incidence in a growing elderly population and improved survival due to
advances in detection and treatments [3].
Heart failure is defined as the inability of the heart to pump enough blood
to meet the metabolic demands of the body. The etiology and clinical features
are complex. Heart failure can result from filling and/or ejection abnormalities,
caused by conduction, structural and/or functional alterations in the pericardium,
myocardium, endocardium, valves, or vasculature [4,5]. Signs and symptoms are
similarly complex and not specific to heart failure. Patients may present with
dyspnea, exercise intolerance, fatigue, and fluid retention, although their
manifestations are highly varied [4,6]. Many patients with heart failure remain
asymptomatic.
The majority of signs and symptoms of heart failure are caused by
reduced left ventricular (LV) function. In fact, LV ejection fraction (EF) of <35% or
<40% is often used as a cutoff to classify heart failure with reduced EF (HFrEF)
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versus heart failure with preserved EF (HFpEF) [4,6]. HFrEF, or systolic heart
failure, comprises about half of the heart failure population and is better
understood than HFpEF, or diastolic heart failure [5]. This cutoff is prognostic and
often used for enrollment into randomized controlled clinical trials [5], meaning
efficacy for new treatments has been shown in HFrEF patients only [4]. The
major influence of the LV in heart failure development, prognosis, and treatment
is the motivation for focusing this project on investigating the LV only.

Cardiac Remodeling
Cardiac remodeling is the alteration of the structure (geometry, shape, and
mass) and ultimately physiological function (contraction and relaxation) of the
heart [7]. Particularly in the LV, remodeling is now appreciated as an important
determinant in the progression and severity of heart disease to heart failure.
Remodeling is a physiologic or pathophysiologic process mainly affecting the
myocytes, but also the interstitium, fibroblasts, collagen, and vasculature in the
ventricle [7]. Causes include, but are not limited to, myocardial infarction, volume
or pressure overload, and inflammation.
Following initial myocardial infarct, myocyte necrosis leaves reduced
cellular mass and an area of thinned LV wall. In the first hours to weeks, the
infarct region typically undergoes disproportionate thinning and dilation, known
as infarct expansion [8-10], with a loss of regional myocardial mass [11].
Chronically, whole chamber dilation may follow, leading to increased end
diastolic (EDV) and end systolic volumes (ESV) while restoring myocardial mass
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to pre-infarct levels [12,13]. Increased chamber volume leads to volume overload
in remote areas, causing hypertrophy in non-infarct zones [9]. These remodeling
events aid in the maintenance of ejection fraction [12] and cardiac output [14],
despite reduced contractility of the infarct segments, but at the cost of increased
chamber volumes. Some patients may eventually progress to noncompensatory
dilation and remodeling which leads to reduced EF [14] and can proceed to
HFrEF.
Hemodynamic overload increases myocyte stretch, a mechanical signal
that initiates a complex intercellular cascade leading to cardiomyocyte growth
and hypertrophy [15]. Systemic hypertension leads to pressure overload, causing
elevated LV wall stress. This is counteracted by increasing wall thickness and
mass. The resulting structural pattern is labeled concentric hypertrophy, in which
LV chamber size, EDV and ESV [16], and cardiac output are reduced [15].
Thickened walls may also be stiffer thus unable to relax and fill with blood,
leading to diastolic heart failure. Another pattern of LV growth—eccentric
hypertrophy—is characterized by increased chamber size in conjunction with
increased LV mass [15,16]. Often caused by volume overload, the LV wall
responds by dilating, allowing preserved cardiac output and relatively normal wall
thickness [16]. A third pattern of remodeling—concentric remodeling—has been
described as normal LV mass with increased wall thickness [16]. While mass is
unchanged, the decrease in chamber size leads to reduced cardiac output.
Overall LV mass increases, independent of body size, as measured by left
ventricular mass index (LVMI) are prognostic of clinical events and cardiac death
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[17,18]. To support hypertrophic cardiomyocytes and their coordinated
contraction, connective tissues of the extracellular matrix must remodel in parallel
[19]. While initially adaptive, this matrix remodeling process can become
pathological and lead to increased deposition of collagen in conjunction with
hypertrophy (see Cardiac Fibrosis below).
Additional causes can lead to pathological remodeling similar to those
described above. Dilated cardiomyopathy, for example, may be idiopathic or due
to non-ischemic influences such as heredity or alcoholism [20]. Hypertrophic
cardiomyopathy may also be idiopathic or inherited [7,21]. Following
hemodynamic or injurious insult, however, remodeling is an adaptive process to
maintain cardiac function. The transition from compensatory to maladaptive
remodeling may contribute to heart failure progression and deteriorating
prognosis [7].

Cardiac Fibrosis
In healthy hearts, cardiomyocytes are surrounded by a lattice-like matrix of
proteins and molecules along with other cell types like cardiac fibroblasts [22].
This extracellular matrix provides a scaffold for shape and structure and is
required for proper function of the ventricles by assisting conduction and force
generation. The equilibrium of the extracellular matrix, which consists primarily of
collagen type I, is responsible for maintaining proper cardiac stiffness for efficient
contraction and relaxation [23]. Cardiac fibrosis occurs from the remodeling of
extracellular matrix and subsequent increase in collagen deposition.
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Similar to and often in conjunction with structural remodeling, collagen
deposition is a compensatory process to maintain proper ventricular stiffness.
This is evident in myocardial infarction where necrotic cardiomyocytes are
replaced with collagen [24] to form a dense scar. Fibrotic tissue protects the
ventricle from rupture [25] and increases stiffness to maintain pump function.
This replacement fibrosis process is typically characterized by a dense, focal
pattern of scar.
Reactive fibrosis is a progressive process that develops from an increase
in collagen production by cardiac fibroblasts [26]. Unlike replacement fibrosis,
reactive fibrosis is characterized by a diffuse interstitial distribution. Hypertension,
diabetes [27], and aging [22] contribute to the expansion of extracellular matrix
and subsequent collagen deposition. Pressure overload induced hypertrophy (as
seen in hypertension [28]) and hypertrophic cardiomyopathy [29] are also
associated with diffuse, reactive fibrosis. Fibrosis has also been identified in
volume overload-induced ventricular dilation without ischemia [30] and in dilated
cardiomyopathy [31]. As described previously, infarcted hearts may also develop
hypertrophy in remote zones [9] requiring subsequent adaptation by the
extracellular matrix. Thus increased collagen content may also arise in this noninfarcted tissue of ischemic hearts [31,32], particularly in areas of hypertrophy.
While reactive fibrosis can occur simultaneously or subsequently in
structural remodeling, there is discrepancy whether dilation or hypertrophy
directly correlates with fibrosis. An increase in collagen content is not absolute in
areas of hypertrophy following myocardial infarction [24] or hypertension [33].
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Septal thickness and overall heart size are common clinical indicators of
hypertrophy and often used as surrogates for fibrosis, yet some have found a
lack of association with fibrotic burden [33]. While fibrosis is presumed to follow
hypertrophy, there is also evidence that fibrosis can actually precede some forms
of hypertrophy [34]. Particularly in the context of hypertrophy, then, myocardial
fibrosis is not directly explained merely by growing cardiomyocytes [33]. Other
unknown factors must be contributing to the development of reactive fibrosis.
Importantly, fibrosis can lead to ventricular stiffening [35,36], which
impacts pump function. Progressive collagen deposit causes stiffening, which
typically affects diastolic relaxation followed by systolic contraction [37]. Fibrosis
also disrupts the syncytium formed by healthy cardiomyocytes by isolating
bundles of cardiomyocytes and disrupting gap junctions. The physical separation
and disconnection of cardiomyocytes slows conduction and wave propagation,
increasing the susceptibility to conduction block, which can initiate reentry and
arrhythmia [38]. Thus, increased fibrosis is linked to worsening heart failure,
arrythmogenesis, mortality risk [33], and sudden cardiac death [39].

Chronic Kidney Disease and End Stage Renal Disease
Epidemiology and Etiology
Over 13% of the United States adult population has persistent reduction of
kidney function, or chronic kidney disease (CKD) [40]. Commensurate with
current national health epidemics, primary risk factors for CKD include diabetes,
hypertension, cardiovascular disease, and obesity [40]. Likely due to these
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comorbidities, Blacks/African Americans are disproportionately affected by CKD.
The severity of CKD is categorized by stages based on estimated glomerular
filtration rate (eGFR) and albumin clearance. Patients are diagnosed with CKD if
eGFR <60 ml/min/1.73m2 or urine albumin/creatinine ratio >30mg/g over
persistent measurements. Patients who reach eGFR<15ml/min/m2 are
considered CKD Stage 5, or complete renal failure. At this point, patients may be
classified as end stage renal disease (ESRD), which indicates that they require
renal replacement therapy for survival [41].
ESRD affects over 600,000 American adults and lends over $87 billion to
total Medicare costs [42]. While overall incidence has plateaued, incident cases
in middle aged and especially elderly populations are on the rise [40,41]. The
leading primary causes of ESRD are diabetes, hypertension, glomerulonephritis,
and cystic kidney disease [40]. Diabetes and hypertension as primary cause of
ESRD are drastically higher in Blacks/African Americans than any other race
[40].

Treatments
Each year, over 100,000 patients begin renal replacement therapy for
treatment of ESRD [40,42,43]. Of patients initiating renal replacement therapy,
nearly 90% receive hemodialysis treatment, but peritoneal dialysis (9%) and
kidney transplants (3%) are increasing [42], especially in younger patients [40]. In
patients on hemodialysis, death rates are highest in the first year of treatment,
then after a drastic drop at year 2, steadily increase over at least the next 5 years
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[42]. Cardiovascular events are the leading cause of deaths in patients on
hemodialysis for ESRD, encompassing over 50% of the known causes of death
[44]. Within 3 years of ESRD therapy, only about 50% of patients are still alive
[41].

End Stage Renal Disease and Cardiac Risk
The term cardiorenal syndrome has been used to describe the combined
failure of both heart and kidneys [45]. Five types have been identified based on
the influence of and outcome in each organ. Cardiorenal Type IV comprises CKD
as an independent cause of heart failure [45]. Renal dysfunction worsens
hypertension, increases fluid retention, and elevates circulating uremic toxins.
Thus, ESRD contributes to volume overload, pressure overload, and
cardiomyopathy [46]. These are the fundamental causes of cardiac remodeling,
resulting in eccentric hypertrophy, concentric hypertrophy, and dilation,
respectively, and promote the transition toward heart failure and possibly death.
In fact, cardiovascular disease is the leading cause of death in patients with
ESRD [42]
Hemodialysis exacerbates many cardiovascular risks in patients with
ESRD. One in 4 patients on hemodialysis will die from sudden cardiac death [43].
For long term hemodialysis patients, risk of cardiovascular mortality is 10-20
times greater than the general population [47]. Unique risk factors for sudden
cardiac death include hyperphysiologic swings in electrolytes and blood volume
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[48,49]. Extreme blood volume removal during hemodialysis may also lead to
hypotension, cardiac stunning [50], and repeated ischemic events [45].

End State Renal Disease and Cardiac Fibrosis
Patients with ESRD almost ubiquitously develop dilation [51] and/or
hypertrophic [52] remodeling but fibrosis is not certain. Hypertrophy seems to
develop early in CKD, prior to hemodialysis initiation [53] and progresses with
deteriorating eGFR [54]. Previous reports describe a varied but large
proportion—up to 91% [55]—of hemodialysis patients who are hypertrophic [5658]. In hemodialysis patients, hypertrophy is associated with poorer systolic
function [58] and worse prognosis. Elevated blood pressure and ventricular
dilation—likely from chronic volume overload—associates with increased LV
mass [56,57], making the interplay between patterns of structural remodeling
complex.
Myocardial infarction prevalence is about 14% in hemodialysis patients,
yet cause of death is most often attributed to sudden cardiac death, not
myocardial infarction [47]. While a fraction of patients on hemodialysis develop
replacement fibrosis following myocardial infarction, a larger proportion develop
reactive fibrosis, which can occur with or without infarct [59].
Similar to the cardiac patient population, CKD patients can demonstrate
fibrosis irrespective of hypertrophy [60]. It has been shown that diffuse fibrosis
may not correlate with systolic function or low EF [58]. While an autopsy study
revealed an association between fibrosis and hemodialysis vintage [61] (time of
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hemodialysis treatment) others have not found a similar correlation [58]. It is
understood that patients on hemodialysis with a greater fibrotic burden (>30% of
tissue area) have significantly worse prognosis [51], despite the lack of
association with systolic dysfunction. In fact, in a multivariate analysis including
hypertension, diabetes, ejection fraction, LV dilation, and cardiomyocyte
hypertrophy as predictors, only the percent area of LV fibrosis emerged as an
independent predictor of cardiac death [51]. An experimental model in rabbits
also linked induced renal failure to arrhythmias and increased fibrosis [62].
Therefore, cardiac fibrosis is an independent risk factor for death above and
beyond the structural remodeling seen in patients with ESRD. As articulated by
McCullogh et al., cardiac fibrosis is a common and significant substrate for pump
dysfunction and sudden cardiac death due to arrhythmia, the two leading
mechanisms of death in ESRD [45].

Measuring Cardiac Fibrosis
Tissue Biopsy
Since fibrosis is a crucial element in cardiac disease and heart failure,
accurate measurement is essential for proper diagnosis, treatment selection, and
survival—particularly in the ESRD population. The historical gold standard for
fibrosis identification is collagen volume fraction measured by myocardial tissue
biopsy. Biopsy studies in ESRD patients have identified cardiomyocyte
hypertrophy along with replacement [50] and diffuse fibrosis [51,63,64].
Unfortunately, this technique is prone to falsely report the absence of fibrosis
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[65], likely due to the heterogeneity of the disease. Additionally, clinicians must
assume fibrotic content of non-biopsied regions from small tissue samples. Aoki
et al. report a mean percent area of fibrosis in myocardial samples in
hemodialysis patients that is only slightly elevated (22%) compared to controls
(21%) [51], which highlights that wide distribution of fibrosis leaves biopsy
susceptible to false underestimations of true, global fibrotic burden. The
invasiveness of the biopsy procedure also renders it unsuitable for serial
measurements, which is critical for monitoring the actively remodeling hearts of
patients with ESRD.

Echocardiography
Echocardiography is a widely available technology with the ability to
rapidly acquire measurements of LV mass and monitor systolic and diastolic
function. Due to the prevalence of LV hypertrophy in the ESRD population,
echocardiography has been widely adopted for measurement of cardiac
remodeling and dysfunction. Measures of mass and volume are obtained for
assessment of hypertrophy and dilation as well as LV function assessed by EF
[66]. Using deformation imaging, echocardiography can measure LV dysfunction
through strain and strain rate measurement in radial, circumferential, and
longitudinal directions to identify systolic dysfunction [67]. Diastolic dysfunction
can be assessed by comparing early (E) and late (A) diastolic strain via the E/A
ratio and is predictive of outcomes [67]. Location and extent of infarct patterns
may be identified by wall reduced tissue velocity [66].
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Due to the potential correlation between hypertrophy, dysfunction, and
fibrosis, echocardiography has been extended to the assessment of fibrosis in
patients with ESRD. The unique and hyperphysiologic hemodynamic variations
experienced by patients with ESRD can influence the accuracy of
echocardiography. Measurements via echocardiography depend on both loading
conditions and an assumed symmetric geometry of the LV [52], which is
problematic for the dynamically shifting blood volumes and remodeling ESRD
heart. It has been shown that echocardiography systematically overestimates LV
mass and volumes in patients on hemodialysis [52,68]. Since hypertrophy is
often used as a correlate for fibrosis, this overestimation not only impacts the
understanding of structural remodeling, but also the assumption of cardiac
fibrotic burden in ESRD. While this noninvasive method is preferred over biopsy,
echocardiographic functional biomarkers such as E/A ratio may be unable to
distinguish cardiac fibrosis as measured by histology [51], leaving this technology
unsuitable for fibrosis identification in patients with ESRD.

Contrast Enhanced Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (CMR) with gadolinium contrast
agents has emerged as the new clinical standard for detecting fibrosis,
particularly following myocardial infarction, using a technique called late
gadolinium enhancement (LGE) [69-71]. Gadolinium is an extracellular contrast
agent, delivered intravenously. Upon perfusion into the myocardium, gadolinium
accumulates in areas of expanded interstitial space, which occurs during the
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development of fibrosis [72]. It shortens the T1 (longitudinal) relaxation of protons
associated with nearby water molecules, leading to an increase in signal intensity
in magnetic resonance imaging (MRI). Slower kinetics and increased
concentrations of gadolinium in fibrotic areas can be detected as enhancement
on images 5-20 min after contrast agent injection [72]. Thus, LGE creates
contrast between fibrotic and healthy myocardial tissue, where gadolinium
washes out more quickly.
While adequate for identifying focal fibrosis, relatively low levels of signal
enhancement preclude the identification of diffuse fibrosis by LGE [63].
Combining LGE with T1 mapping techniques allows for calculation of
extracellular volume fraction and determination of diffuse fibrosis [73-76]. T1
relaxation time is shortened in proportion to the local concentration of gadolinium.
The absolute T1 time in all myocardial voxels is measured to expose subtle
changes in gadolinium concentration due to interstitial volume expansion and
fibrosis [72]. Gadolinium distributes into all extracellular fluid in the body, so by
correcting for hematocrit, the extracellular volume (ECV) fraction of the
myocardium can be calculated. ECV represents a quantitative measure of fibrotic
burden and has been applied in a wide range of cardiac diseases [77] and
validated with histological comparison of collagen volume fraction [63,78].
Increased ECV is also associated with mortality in cardiac patients [79].
Shortened post-contrast T1 times and increased ECV, consistent with diffuse
fibrosis, have been correlated with ventricular stiffness, or diastolic dysfunction
[64,80].
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Contrast enhanced CMR plays an important role in tissue characterization
and therefore differential diagnosis for cardiac patients with a wide variety of
pathologies [72]. Reactive fibrosis in non-infarcted myocardium as measured by
ECV is prognostic and has been associated with heart failure and death,
independent of EF [81]. ECV measurement of fibrosis may also add incremental
prognostic value on top of the well-established clinical risk factors for heart failure
such as reduced EF, renal dysfunction, heart failure severity, and age.
Contrast enhanced CMR has been used to define patterns of fibrosis in
patients with ESRD. Schietinger et al. described prevalent enhancement at LGE
in hemodialysis patients, specifically identifying 3 patterns of fibrosis: (1)
transmural enhancement consistent with an infarct pattern, and the more
frequent non infarct-related (2) circumferential, diffuse enhancement, and (3)
focal enhancement of the midwall [59]. In this study, LGE correlated with
hypertrophy and systolic dysfunction on a global and segmental level, while a
nonsignificant trend emerged for LGE and hemodialysis vintage. In a similar
study, Mark et al. described 2 patterns of LGE, corresponding to ischemic
(replacement) and non-ischemic (reactive) causes with high prevalence in ESRD
patients [58]. Either type of LGE correlated with greater LV mass and dilation.
Focal LGE associated with systolic dysfunction, while diffuse fibrosis did not. It is
clear that a high rate of cardiac fibrosis is present in the ESRD population with
varying structural and functional correlates.
In 2006, the U.S. Food and Drug Administration (FDA) issued several
public health advisories resulting in updated product labeling and exclusion of
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patients with renal insufficiency from gadolinium based imaging techniques
[82,83]. These warnings resulted from the observation of nephrogenic systemic
fibrosis in patients with ESRD supposedly caused by gadolinium [84] . Further
evidence has established a causative role for gadolinium in the development of
nephrogenic systemic fibrosis [84-87]. Despite the overwhelming benefits of LGE
CMR for the identification of fibrotic burden and patterning, it is now unsuitable
for use in patients with ESRD.
Given the severe limitations in direct fibrosis measurement, the current
dogma leans on the potential correlation between fibrosis and hypertrophy or
dysfunction to predict fibrosis in patients with ESRD. The field has now reverted
to non-contrast CMR or echocardiographic measurements of increased
myocardial mass and reduced strain as surrogate measures of fibrosis.

Non Contrast Cardiac MRI
Native T1 mapping without gadolinium is emerging as a non-contrast
technique for tissue characterization [88,89], with valuable application for patients
with ESRD [90]. As mentioned previously, T1 relaxation time measures the
longitudinal relaxation of protons associated with water molecules. T1 is
calculated using a curve-fitting algorithm based on samples taken at multiple
inversion times [91]. The interstitial expansion occurring concomitantly with
fibrosis development leads to an increase in extracellular water fraction, which
can be detected as lengthened T1 times compared to healthy tissue. Modified
Look-Locker inversion recovery (MOLLI) sequences are now widely used to
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measure and map native T1 relaxation in a single acquisition during in CMR [92].
Using a threshold technique, native T1 mapping can distinguish infarcted tissue
from normal tissue, in agreement with LGE, to identify replacement fibrosis [93].
Maps of T1 relaxation time allow both visual and quantitative analysis of fibrosis
and have been correlated with histology [94] and contrast enhanced CMR
measures of ECV [95,96]. T1 mapping in non-ischemic cardiomyopathy was
correlated with dilation, ECV, and dysfunction [97], revealing a potential
prognostic value for native T1 mapping. Others have shown no correlation
between native T1 and histology [63] or calculation of ECV [98] though.
In a large study of patients with early CKD but not yet on dialysis, native
T1 was increased and correlated with reduced strain but not LV mass [60].
Smaller reports of myocardial native T1 studies in patients on hemodialysis for
ESRD are beginning to emerge [90,99]. Rutherford et al. demonstrated
prolonged native T1 times along with hypertrophy and reduced strain in patients
on hemodialysis [90]. Elevated T1 correlated with ventricular mass but not
reduced strain. A recent case report also demonstrated the identification of nonischemic, reactive fibrosis patterns in one hemodialysis patient [99],
demonstrating the utility of native T1 to identify specific patterns of fibrosis.
Larger studies are warranted to investigate the role of T1 mapping in
hemodialysis patients and its correlation with other cardiac remodeling
measures.
T1 mapping sequences are highly variable across centers resulting in
varied reports of healthy myocardial T1 times [100]. T1 times in disease states
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may be even more variable than healthy populations [101], leading to uncertainty
in the accuracy for fibrosis identification. Ongoing efforts aim to standardize
acquisition procedures and improve accuracy of normal myocardial T1 times so
comparisons between sites and studies are more robust [96,100,102]. Heart rate
variability, a common occurrence in ESRD, is a concern in T1 mapping,
especially for long T1 values [91]. Additionally, the need to sample over multiple
inversions, through a number of cardiac cycles, requires aggressive motion
correction to be employed [103]. Due to motion correction artifacts, T1
quantitative analysis has been predominantly limited to the interventricular
septum [94,95,104]. It is known that patients on hemodialysis also tend to
develop anemia which can exacerbate hypertrophy [105] and arbitrarily elevate
native T1 times. Without correction for hematocrit, T1 mapping may not be an
accurate fibrosis measurement option in this group.
Another non-contrast technique—magnetization transfer (MT) MRI—is
emerging for myocardial tissue characterization. During standard clinical imaging
using cine balanced steady state free precession (bSSFP) MRI, the transfer of
saturated magnetization from extracellular matrix macromolecules to the
surrounding bulk water occurs through a process called magnetization transfer
(MT) [106], which reduces the myocardial signal intensity [107,108]. Expansion of
extracellular water volume, which occurs concomitantly with progression of
fibrosis, causes reduction in MT and subtle elevation of myocardial signal
intensity. This endogenous contrast mechanism can be exploited for gadolinium
free CMR fibrosis imaging.
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Simple visual identification of these myocardial signal elevations is
challenging because of the subtle differences between healthy and fibrotic tissue.
Advanced analysis of bSSFP images is required to extract the differences in MT
caused by fibrosis. Two images with high and low MT-weighting are required.
MT-weighting can be modulated by altering the radiofrequency (RF) pulse
duration or flip angle such that long RF pulse duration or high flip angles (to a
threshold) generate greater amounts of MT [108]. A pair of images is acquired
with and without an off-resonance RF pulse [109] or at low and high flip angles to
produce weak and strong MT effects, respectively. Effects of MT are typically
measured as a ratio of signal intensity (SI) and presented as a percent following
the formula: MT ratio=(SIweakMT – SIstrongMT )/ SIweakMT x100% [107]. Voxel-wise
maps of MT ratio are generated to visually represent the alterations in myocardial
MT allowing quantitative analysis per segment, slice, or whole ventricle. Notably,
since MT-CMR is conducted using standard clinical bSSFP images, concurrent
assessment of ventricular tissue characterization, structure, and function is
possible.
MT effects have been investigated in select studies for cardiac fibrosis
identification. In an experimental myocardial infarction model in rats, nuclear
magnetic resonance measured the reduction of MT in acute and chronic
myocardial infarction [110]. Vandsburger et al. described the identification and
monitoring of scar formation by measurement of reduced MT ratio following
induced myocardial infarction in mice [111]. MT-CMR showed excellent spatial
association with LGE in this model. A study by Weber et al. in human participants
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demonstrated uniform MT ratio in healthy myocardium, decreased MT ratio in
infarcted tissue, and strong spatial agreement with LGE [108]. MT-CMR shows
substantial promise for gadolinium free myocardial fibrosis measurement in
patients with ESRD. The ability to combine structural, functional, and tissue
characterization measurement in a single imaging technique means MT-CMR
may be the key to multiscale study of fibrosis and its association with ventricular
remodeling and dysfunction in hemodialysis patients with ESRD.

Summary
Patients with ESRD experience unique risk factors of heart failure and
sudden cardiac death, unlike the general cardiac patient population. Clinical
predictors of heart failure and sudden cardiac death are well established for
cardiac patients but are complicated by comorbidities and unique exposures
introduced by ESRD and hemodialysis treatment. Though these patients are
highly attended in frequent hemodialysis treatment, the understanding of heart
failure and sudden cardiac death in patients with ESRD remains obscure.
Patients with ESRD, clearly suffer from a unique cardiomyopathy that is linked to
their complex disease and treatment states. The current dogma treats
hypertrophy or reduced strain as reliable surrogate measures of cardiac fibrosis
in patients on hemodialysis. Conflicting evidence in a variety of studies illustrates
the complex interaction and independence between structural remodeling,
contractile dysfunction, and fibrosis while highlighting the inappropriateness of
these dogmatic surrogate measures for fibrosis identification. While highly
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related, hypertrophy, strain, and fibrosis should be treated as separate
manifestations of a multifaceted disease.
The exclusion of patients with ESRD from gadolinium enhanced CMR
greatly hinders the capacity to safely identify and monitor fibrosis. Absence of a
suitable cardiac fibrosis diagnostic has limited the understanding of heart failure
in the setting of ESRD and obstructed development and testing of potential
therapies in this unique population. Development of a gadolinium free and
quantitative method of fibrosis detection could overcome this critical barrier and
present better diagnostic and monitoring options to propel the development of
targeted therapies. Accurate and safe measurement of fibrotic burden and
distribution could inform appropriate pharmaceutical interventions or serve as
selection criteria for alternative treatments such as radiofrequency ablation and
implantable cardioverter-defibrillator to prevent arrhythmias and ultimately reduce
the risk of sudden cardiac death in patients with ESRD. The following project
describes the development of a gadolinium free, MT-CMR technique and its
application for cardiac fibrosis measurement and monitoring in patients with
ESRD.

Copyright © Tori Ann Stromp 2016
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CHAPTER 2: GADOLINIUM FREE CARDIAC MAGNETIC RESONANCE
IMAGING WITH 2-POINT CINE BALANCED STEADY STATE FREE
PRECESSION

Preface
This chapter is reprinted from: Stromp TA, Leung SW, Andres KN, Jing L,
Fornwalt BK, Charnigo RJ, Sorrell VL, and Vandsburger MH. Gadolinium Free
Cardiac Magnetic Resonance Imaging with 2-point Cine Balanced Steady State
Free Precession. Journal of Cardiovascular Magnetic Resonance. 2015; 17.

Alterations were made in agreement with the formatting requirements dictated by
the University of Kentucky Graduate School and for clarity and continuity of this
dissertation.
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Synopsis
Background: MRI of ventricular structure and function is widely performed using
cine balanced steady state free precession (bSSFP) MRI. The bSSFP signal of
myocardium is weighted by magnetization transfer (MT) and T1/T2-relaxation
times. In edematous and fibrotic tissues, increased T2 and reduced MT lead to
increased signal intensity on images acquired with high excitation flip angles. We
hypothesized that acquisition of two differentially MT-weighted bSSFP images
(termed 2-point bSSFP) can identify tissue that would enhance with gadolinium
similar to standard of care late gadolinium enhancement (LGE).

Methods: Cine bSSFP images (flip angles of 5º and 45º) and native-T1 and T2
maps were acquired in one mid-ventricular slice in 47 patients referred for
cardiac MRI and 10 healthy controls. Afterwards, LGE images and post-contrast
T1 maps were acquired and gadolinium partition coefficient (GPC) was
calculated. Maps of ΔS/So were calculated as (S45-S5)/S5*100 (%), where
Sflip_angle is the voxel signal intensity.

Results: Twenty three patients demonstrated areas of myocardial hyperenhancement with LGE. In enhanced regions, ΔS/So, native-T1, T2, and GPC
were heightened (p<0.05 vs. non-enhanced tissues). ΔS/So, native-T1, and T2 all
demonstrated association with GPC, however the association was strongest for
ΔS/So. Bland-Altman analysis revealed a slight bias towards larger volume of
enhancement with ΔS/So compared to LGE, and similar transmurality. Subjective
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analysis with 2-blinded expert readers revealed agreement between ΔS/So and
LGE of 73.4%, with false positive detection of 16.7% and false negative detection
of 15.2%.

Conclusions: Gadolinium free 2-point bSSFP identified tissue that enhances at
LGE with strong association to GPC. Our results suggest that with further
development, MT-weighted CMR could be used similar to LGE for diagnostic
imaging.
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Background
Cardiac magnetic resonance imaging (CMR) has become a reference
standard modality to image ventricular structure, contractile function, and
perfusion [112]. Combined with intravenous administration of gadolinium contrast
agents, late gadolinium enhancement (LGE) – CMR has become the standard of
care to identify myocardial edema, necrosis, and focal fibrosis. The presence of
LGE correlates with significantly increased risk of adverse cardiac events and
mortality [113]. Recent studies that identify diffuse fibrosis through measurement
of gadolinium partition coefficient (GPC) or the extracellular volume fraction
(ECV) [77,114] have similarly demonstrated a strong correlation between diffuse
fibrosis and increased mortality [115]. However, residual concerns surrounding
gadolinium and nephrogenic systemic fibrosis [116] have spurred the
development of gadolinium free methods to identify diseased myocardium.
Both edematous and fibrotic myocardium are characterized by an
increased extracellular volume fraction, which results in lengthened native-T1
and T2-relaxation times compared to healthy myocardium. These changes have
been used to identify edema in acute MI [117,118] and fibrosis in select
cardiomyopathies [119-121]. Recent studies using native T1-mapping to identify
fibrosis are highly promising [122-124]. However, measured myocardial T1relaxation times vary between T1-mapping pulse sequences [125] and
myocardial regions [126], require special sequence modifications to reduce
arrhythmia sensitivity [127], and reconstruction of T1-maps requires motion
correction [128] that has limited some prior measurements to the septum
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[119,121,129,130]. In contrast, cine balanced steady state free precession
(bSSFP) is ubiquitously used to image ventricular structure and function. While
weighting of the bSSFP signal by a factor of √T2/T1 is established, modulation of
the bSSFP signal by magnetization transfer (MT) from extracellular matrix
macromolecules has only recently been understood [131,132]. Specifically,
myocardium characterized by increased ECV demonstrates reduced MT
compared to healthy myocardium, as demonstrated in a prior study of acute-MI
[131]. However, whether MT-weighted CMR can be used to identify tissues that
would enhance with gadolinium across a range of cardiomyopathies similar to
LGE has not been examined.
We hypothesized that acquisition of bSSFP cine image sets with different
MT-weighting (termed 2-point bSSFP) could combine the changes in signal
intensity due to both lengthened T1/T2-relaxation and reduced MT to identify
tissue that would enhance with gadolinium in close agreement to LGE. We
compared tissue characterization with 2-point bSSFP, native-T1 and T2-mapping
to LGE in 47 patients referred for cardiac MRI at our institution. Our results
demonstrate robust agreement between gadolinium free 2-point bSSFP imaging
and standard of care LGE, with a strong association between 2-point bSSFP and
GPC.
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Methods
Patient Selection, Ethics, Consent and Permissions
Fifty non-consecutive patients referred for clinically indicated CMR with
gadolinium contrast were prospectively enrolled, however 3 were excluded due
to inability to maintain breath-holds. All patients referred for CMR with gadolinium
contrast at our institution over a six month period were approached for study
participation, with the forty seven included in the study representing those that
consented to participate. Afterwards, ten healthy age-matched controls were
recruited but did not receive gadolinium. The research protocol was approved by
our institutional review board (IRB 13-0914-F2L) and informed consent was
obtained from all subjects for participation and publication of findings.
Demographic characteristics are summarized in Table 1. Clinical CMR reports
were used to obtain ejection fraction (EF), end-diastolic volume (EDV), and CMR
diagnosis.

Cardiac MRI Protocol
CMR was performed on a 1.5T Siemens MAGNETOM Aera scanner
(Siemens Medical Imaging Solutions, Erlanger, Germany) using an 18 channel
body coil and 12 channel spine coil. A short-axis stack of bSSFP cine images
were obtained with prospective ECG triggering to cover the entire heart (TE:
1.2ms TR: 3.2ms, bandwidth: 930Hz, field of view: 260x260mm, slice thickness:
8mm, flip angle: 50°, 256x256matrix, GRAPPA 2), from which one midventricular slice was identified for further imaging. The signal intensity of bSSFP
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images acquired with high excitation flip angles and short repetition times is
heavily weighted by MT, T1 and T2, while identical images acquired with low flip
angles reflect proton density weighting with minimal contributions from MT. In the
identified slice, pairs of bSSFP cine images were acquired with excitation flip
angles of 5° (proton density reference) and 45° (MT, T1, T2-weighted) during
end-expiratory breath-holds. Native myocardial T1-relaxation times were
assessed using a modified Look-Locker imaging (MOLLI) sequence (5(3)3,
TE:1.1ms, TR:2.7ms, flip angle:35°, bandwidth:1085Hz, field of view:272x
272mm, slice thickness:8mm, 256 matrix with 66% phase resolution, partial
Fourier transform 7/8, GRAPPA 2). T2-relaxation times were assessed using a
gradient echo readout (T2 preparations of: 0ms, 25ms, 55ms with 3 heart beat
recovery in between, TE:1.1ms, TR:3.2ms, bandwidth:1184Hz, field of
view:272x272mm, slice thickness:8mm, 192 matrix with 75% phase resolution,
partial Fourier transform 6/8, GRAPPA 2) in the same short axis slice during
diastasis. Afterwards, gadolinium (0.2mmol/kg Gd-DTPA) was administered
intravenously as a bolus (rates ranged from 2ml/s to 5ml/s) and after 15 minutes
LGE images were obtained using segmented gradient recalled echo inversion
recovery (TE:3.2ms, TR:8.3ms, flip angle:25°, Bandwidth:140Hz) with inversion
time set to optimally null the myocardium. Finally, post-contrast MOLLI
(4(1)3(1)2, TE: 1.1ms, TR: 2.7ms, flip angle: 35°, field of view: 272 x 272mm,
GRAPPA 2) images were obtained in the same slice position as pre-contrast
images. Normal volunteers only underwent non-contrast portions of the protocol.
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Image Analysis
Maps of T1 and T2-relaxation times were automatically reconstructed after
motion correction using non-rigid body correction. The reproducibility of breathhold position and the degree of mis-alignment between 5° and 45° scans was
assessed via calculation of the DICE similarity coefficient for both complete
images and segmented images in which only the heart was included. 2-point
bSSFP data was analyzed by calculating the normalized change in signal
between images as (ΔS/So)i=[(S45-S5)/S5]i, where S45 and S5 represent the signal
intensity for 45° and 5° excitations respectively for each cardiac phase (i). For
each patient ΔS/So maps from 3 diastolic phases without cardiac motion were
averaged together to reduce random noise. Maps of GPC were calculated as
GPC=(ΔR1,myocardium/ΔR1,blood) from reconstructed T1-maps.
Data from patients receiving gadolinium were divided and analyzed in a doubleblinded manner. An SCMR level-III reader (SWL) used a custom designed
MATLAB script to segment the myocardium and define a non-enhanced region of
interest (ROI) in each LGE image. Myocardial voxels with signal intensity greater
than 5 standard deviations (SD) above the mean of the defined ROI were
classified as enhanced at LGE. Maps defining LGE-enhanced and non-enhanced
regions were saved, transmitted to MHV, and used to segment ΔS/So, native-T1,
T2, and GPC maps. To avoid partial volume errors and account for minor
differences in spatial resolution, endocardial and epicardial borders were slightly
adjusted to remove the blood pool and pleural space. Measurements in healthy
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controls and patients without LGE-enhancement were performed over all voxels
in the myocardium.
In data acquired from patients demonstrating enhancement at LGE, the
enhanced area was calculated as the percentage of all myocardial voxels
classified within the enhanced ROI. To calculate the enhanced area from maps
of ΔS/So, a threshold value of 197% (representing the mean + 3 standard
deviations of the mean from the healthy control cohort) was applied and used to
calculate the fraction of myocardial voxels above the threshold. Transmurality
was calculated as the percentage of enhancement along the radial direction at
the center of the area of enhancement for LGE and ΔS/So maps.
Figures were prepared using a median filter with a 3x2 kernel. The color
scheme for maps of ΔS/So and native-T1 used in Figures 2.1-2.5 has been
designed to emulate LGE, with non-enhanced tissue appearing dark, enhanced
tissue appearing bright, and tissue that would demonstrate diffuse “gray”
enhancement appearing red/yellow.

Subjective Assessment by Blinded Readers
Subjective assessment of 2-point bSSFP in comparison to LGE was
performed by two blinded readers with 1 and over 10 years’ experience. All
ΔS/So maps and LGE images were compiled separately and randomized. The
readers were asked to identify the presence, location, and type (focal vs. diffuse)
of enhancement, and to delineate the extent of enhancement on each image.
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Statistics
Numeric data are summarized as mean ± SD. For outcome variables we
used Version 9.3 of SAS software (SAS Institute, Cary NC) to fit a linear mixed
model comparing mean levels across four groups of heart tissue: healthy controls
(Group I), patients without LGE-enhancement in the imaged slice (Group II), nonenhanced regions of interest from patients with LGE-enhancement (Group III),
and enhanced regions of interest from patients with LGE-enhancement (Group
IV). We included random effects for subjects to account for correlations between
measurements on non-enhanced and enhanced tissue from the same patient
with LGE-enhancement. Linear contrasts were used for pairwise comparisons.
Demographic variables were analyzed using SPSS (IBM Corp., 2013). The
Shapiro-Wilk method was used to test normality of numeric data. Age, body
mass index (BMI), and race were compared across all participants using the
Kruskal-Wallis method. Fisher’s exact tests were used to compare gender across
all participants and CMR diagnosis between the two patient groups. Differences
in EF were compared via Mann-Whitney and EDV was analyzed by student’s ttest. Statistical significance in pairwise comparisons was defined by a p-value <
0.05 divided by the number of comparisons to control Type I testing error through
Bonferroni adjustment. Otherwise, a p-value<0.05 defined statistical significance.

Results
Demographics and Ventricular Structure and Function
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Amongst 23 patients who demonstrated LGE-enhancement in the imaged
slice, EDV trended higher and EF trended lower compared to patients who did
not demonstrate LGE-enhancement (Table 2.1). There were no significant
differences in age or BMI between patients with and without LGE enhancement.
Control participants differed only in BMI compared to patients (p<0.001 for all).

MR Tissue Characterization
The DICE similarity coefficient measured across all patients was 0.995 ±
0.004 when comparing entire 5° and 45° images. Comparison of the same
images following segmentation of only the heart revealed a DICE similarity
coefficient of 0.991± 0.015. Representative bSSFP images and maps of ΔS/So in
a healthy control subject and a patient without LGE-enhancement revealed
uniformly low ΔS/So values across both hearts (Figure 2.1). In patients with acute
(Figure 2.2-2.3) and chronic MI (Figure 2.4), CMR tissue characterization with 2point bSSFP demonstrated heightened ΔS/So values in close spatial agreement
with LGE-CMR enhancement patterns. Representative images acquired in two
patients with non-ischemic dilated cardiomyopathy demonstrate the accurate
detection of fibrotic tissue using 2-point bSSFP (Figure 2.5). Elevated native T1relaxation times were also observed in agreement with LGE following MI (Figures
2.2 and 2.4).
Average myocardial ΔS/So, native-T1 and T2 relaxation-times were
significantly higher in LGE-enhanced regions (Group IV) compared to all nonenhanced regions (Groups II and III) and healthy controls (Group I, Figure 2.6).
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The mean of the standard deviation of ΔS/So values amongst healthy controls
was 27.1 ± 8.1 (%) in absolute terms. Segmentation of the heart into twelve
equal circumferentially spaced sectors revealed moderately lower average ΔS/So
values (118.8 ± 14.7 (%)) in the anterior-lateral wall compared to the rest of the
myocardium. Additionally, GPC was significantly elevated in LGE-enhanced
regions (Figure 2.6). Native-T1 and T2-relaxation times and ΔS/So did not differ
significantly between non-enhanced myocardium in patients (Groups II and III)
and healthy controls (Group I, Figure 2.6). Native-T1, T2 and ΔS/So all
demonstrated strong association with GPC (Figure 2.7).
Quantification of the percent of myocardium classified as enhanced at 2point bSSFP demonstrated a strong association (R2 = 0.84) with the percent of
myocardium classified as enhanced at LGE (Figure 2.8), however a slight bias
towards over-estimation of the enhanced area in patients with a higher
percentage of enhancement was observed. Bland-Altman analysis (Figure 2.8)
revealed a coefficient of covariance of 0.204. Measurement of the transmurality
of enhancement was similar between 2-point bSSFP and LGE (R2 = 0.73), and
Bland-Altman analysis revealed a coefficient of covariance of 0.0875 (Figure
2.8).

Subjective Assessment
Analysis of ΔS/So maps and LGE images by 2 blinded readers revealed
an average agreement of 73.4% between methods. Among the patients
demonstrating enhancement at LGE, the extent of enhancement on ΔS/So maps
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was identified as the same in an average of 67.2% of individuals. The extent of
enhancement was identified as greater in ΔS/So maps in 20.8% of individuals,
and smaller in ΔS/So maps in 12.0% of individuals. An average of 4 out of 24
patients in which enhancement was not identified in LGE images were classified
as demonstrating enhancement on ΔS/So maps (Figure 2.9). Among the 23
patients demonstrating enhanced tissue at LGE, an average of 3.5 were
classified as normal by readers interpreting ΔS/So maps (Figure 2.10). In all such
cases, enhancement patterns were consistent with small sub-endocardial
enhancement at LGE.

Discussion
In this study we present a new 2-point bSSFP method for gadolinium free
CMR. In 47 patients undergoing clinical LGE examination, 2-point bSSFP
demonstrated a strong association between elevated ΔS/So and enhanced
regions in LGE across a range of cardiomyopathies. Further, 2-point bSSFP
demonstrated similar results to mapping of native-T1 relaxation times.
Importantly, in this study we used a relatively simple method to generate MT
contrast in bSSFP images. However, MT contrast can be further enhanced
through the use of additional MT-preparation schemes, potentially increasing the
sensitivity of CMR tissue characterization with MT contrast.
Heightened steady state signal in edematous cardiac tissue occurs in
bSSFP images acquired with a short repetition time and high flip angle. In a
study by Zhou et al. [132], edematous myocardium was visualized as hyper-
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intense on bSSFP images following ischemia-reperfusion injury in dogs. By
comparison to T2-prepared SSFP images, the authors concluded that edema
contrast in bSSFP was dominated by changes in MT and proton density (65%),
with altered relaxation times having a more modest effect (35%). Similarly,
Kumar et al. [133] observed a 50% increase in bSSFP signal in infarcted tissue in
dogs and patients with acute MI. While we observed increased signal intensity in
edematous areas on bSSFP images, we found that visualization required
significant contrast adjustments and resulted in noisy images (Figure 2.3). In 2point bSSFP, changes in signal intensity on standard bSSFP cine images caused
by increased T2 and reduced MT in tissue that enhances at LGE were extracted
by normalization to images acquired with a 5° flip angle (proton density
weighted). Measurement of ΔS/So, which was elevated in enhanced tissue in
patients with acute MI, was consistent with signal intensity changes seen by
Kumar et al. [133] and Zhou et al. [132] and demonstrated strong spatial
agreement with LGE (Figure 2.2). In addition, patterns of heightened ΔS/So in
patients with acute-MI mirrored T2-mapping (Figure 2.3), which is widely used to
identify edema [117,118]. Our results further agreed with Weber et al. [131] who
demonstrated altered MT-ratio in patients with sub-acute MI by acquiring pairs of
bSSFP images with different MT-weighting. In the study by Weber et al. MTcontrast was generated by altering the duration of the RF excitation pulse and
the repetition time between cardiac phases causing reduced MT-ratio in
edematous tissue in comparison to healthy tissue. However, elongation of the
excitation pulse meant that differences in cardiac phase were present in images
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used to calculate the MT ratio. We chose to change the excitation flip angle, and
not duration, in order to have a consistent cardiac phase between MT-weighted
and proton density weighted images. Subsequently, our measure of ΔS/So is
heightened in tissues that would enhance with LGE.
Identification of focal fibrosis with LGE is the established clinical standard
and in our study heightened ΔS/So occurred in tissues identified by LGE as
replacement (Figure 2.4) and reactive fibrosis (Figure 2.5). Emerging techniques
to image diffuse fibrosis including mapping of post-contrast T1-relaxation times
and measurement of GPC or ECV [77,114] have been correlated to collagen
volume fraction at biopsy [134] and demonstrated predictive value for clinically
relevant outcomes [115,135,136]. In our study we did not have access to
hematocrit, however GPC values measured in non-enhanced myocardium
agreed with prior studies of healthy tissue [126,137,138] and were significantly
elevated in regions of interest identified by LGE (Figure 2.6). Comparing ΔS/So to
GPC revealed a strong and promising association (Figure 2.7). However,
detection of diffuse fibrosis with 2-point bSSFP requires further study with a
larger sample and a consistent phenotype such as hypertrophic cardiomyopathy.
In order to further examine the impact of changes in T1 relaxation times
on the steady state signal intensity, a series of simulations of the steady state
magnetization using the closed form equation for cine bSSFP were performed in
Matlab (Figure 2.11). For all simulations we assumed that proton density is 1.
Since bSSFP images are weighted by √T2/T1, increased T1 relaxation times in
fibrotic scar tissue will have the opposite effect of decreased MT on the steady
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state signal in the high flip angle acquisition (Figure 2.11). While this may be
partially mitigated by concomitant increases in T2 relaxation times (Figure 2.11),
the balance between increased T1 and reduced MT, and the potential limits this
imposes upon detection via measurement of ΔS/So, requires additional
examination in a large cohort of patients with chronic MI. In addition, given the
contributions of MT, T1, and T2 to ΔS/So, it is unclear whether measurement of
specific ΔS/So values can be used to differentiate edema from fibrosis. Additional
studies with larger cohorts of acute and chronic MI patients are necessary to
examine this possibility.
Mapping of native myocardial T1-relaxation times is emerging as a highly
promising method for gadolinium free imaging of fibrosis [122,124,126]. Recently,
several studies demonstrated increased T1-relaxation times in patients with
edema [139], aortic stenosis [119], myocarditis [120], and hypertrophic and nonischemic dilated cardiomyopathies [121]. Native T1-relaxation times measured in
our study using a MOLLI acquisition scheme at 1.5T were comparable to those
measured under similar settings [125,140] and were significantly elevated in
enhanced myocardium (Figure 2.6). While we observed a strong association
between heightened native-T1and GPC, our association was weaker than
observed in prior studies [120,121]. One likely factor contributing to this
difference is that unlike most prior studies that focused on patient cohorts with a
specific and profound phenotype, we sampled patients with a range of
cardiomyopathies and varying degrees of edema or fibrosis. Also, artifacts
introduced by motion correction [128] have led many prior studies to restrict data
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analysis to the interventricular septum [119,121,130]. We analyzed myocardium
across an entire short-axis slice, defining regions of interest based on LGE
patterns. Results from a recent multi-center T1 mapping study demonstrated
considerable regional variability in segmental native-T1 values at 1.5T [126].
Thus, our results likely reflect the influence of both motion correction artifacts on
T1-estimation and regional T1 heterogeneity of healthy tissue that were not
included in prior studies. Additionally, our scanner was equipped only with a
MOLLI acquisition scheme that has demonstrated sensitivity to MT-effects [123],
and thus the sensitivity of native T1-mapping may have improved with other
mapping methods now available [125], including recently developed arrhythmia
insensitive T1 mapping protocols [127].
Images acquired with an excitation flip angle of 5° demonstrate low signal
to noise, potentially leading to artificially elevated measurement of ΔS/So. We
sought to limit the effect of random noise by averaging over three identical end
diastolic phases and applying a median filtering algorithm to reconstructed maps.
However, subjective assessment of ΔS/So maps by two blinded expert readers
resulted in the incorrect interpretation of diffuse enhancement in ΔS/So maps in
all but one of the false positive cases (Figure 2.9). We chose to use a 5°
excitation flip angle in order to maximize the potential difference in MT-weighting
between images, however, the acquisition of such images with slightly higher flip
angles may present a more promising route to maintaining MT-contrast between
image pairs while reducing the presence of voxels with spuriously high ΔS/So
values. Alternatively, future studies could examine MT-weighting without the use
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of low flip angle acquisitions via various magnetization preparation schemes that
encode greater MT-weighting directly into the steady state magnetization. In
addition, subjective analysis of ΔS/So maps by expert readers revealed a
propensity to misidentify small sub-endocardial enhancement patterns as blood
instead of enhanced tissue (Figure 2.10). In future studies, the use of blood
signal suppression should be investigated as a mechanism to mitigate fall
negative interpretation of ΔS/So maps.
A limitation to our study was that due to time constraints we acquired data
in only one slice per patient without prior knowledge of disease status. In several
patients, the slice chosen for our study did not demonstrate LGE-enhancement
(Group II), however LGE-enhancement was present in other slices. Additionally,
limitations on T1 and T2-mapping protocols on our scanner resulted in
acquisition of bSSFP images at slightly higher spatial resolution. Consequently,
partial volume error is more likely to influence T2 maps, and to a lesser extent T1
maps, than 2-point bSSFP results. Care was taken to adjust boundaries to
exclude border pixels affected by partial volume artifacts, however registration of
pre and post gadolinium maps was not performed. The sensitivity to B1
inhomogeneity remains a significant concern in cine bSSFP, particularly at higher
flip angles. We simulated the bSSFP signal using a range of myocardial
relaxation times and excitation flip angles. Based on the results of our simulation
(Figure 2.11), and prior evidence that MT is maximal and constant above
excitation flip angles of 30° [131], we chose to use a 45° flip angle in order to
minimize the potential effects of B1-inhomogeneity. Also, changes in through-
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plane motion can modulate steady state behavior in the myocardium. For this
reason we chose to focus our analysis on end-diastolic cardiac phases. In
addition, the acquisition of two separate end expiratory breath-held scans
increases the potential for misalignment between scans. Measurement of the
DICE similarity coefficient between image pairs in our study was high, however
we benefited from placement of our scans at the end of the non-contrast CMR
workup, thus reducing potential misalignment that could occur if such scans were
performed at the initiation of the CMR examination. Importantly, while registration
algorithms can be used to compensate as they are in T1 mapping protocols,
simple image intensity based algorithms would not be effective for registration of
images acquired with a 5° excitation flip angle.
2-point bSSFP utilizes endogenous contrast mechanisms for gadolinium
free CMR imaging. In this study, we demonstrated across a range of patients
strong association between 2-point bSSFP and standard of care LGE-CMR.
Importantly, since MT-contrast is an endogenous mechanism, the sensitivity to
changes in MT-weighting increases with spatial resolution. In addition, MTcontrast can be further increased with MT-preparation schemes not used in this
initial study. In contrast, differences in native-T1 between healthy and diseased
tissue cannot be further increased without increasing the magnetic field strength.
With further development, MT-weighted CMR could potentially enable diagnostic
imaging similar to LGE CMR without the use of gadolinium.
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Table 2.1. Participant Characteristics.

Variable

Demographics
Age (yrs)
2
BMI (kg/m )
Female
White
African American
Hispanic or Other Race
CMR Indication
Cardiomyopathy
Hypertrophic Cardiomyopathy
Pericarditis, Myocarditis
Sarcoidosis
Syncope
Viability
Other
Diagnosis
Ischemic Cardiomyopathy
Non-Ischemic Cardiomyopathy
Cardiomyopathy
No Evidence of Cardiomyopathy
Other
Ejection Fraction (%)
End Diastolic Volume (mL)

Healthy
Control
(Group I)

CVD without
Enhancement
(Group II)

CVD with
Enhancement
(Groups III, IV)

(n=10)

(n=24)

(n=23)

47.7± 16.5
29.3 ± 6.7
8 (33.3)
20 (83.3)
3 (12.5)
1 (4.2)

51.39 ± 15.4
27.4 ± 3.6
4 (17.4)
18 (78.3)
3 (13.0)
2 (8.7)

.406
.007
.315
.815
1.00
.051

7
2
2
2
4
3
4

10 (43.5)
1 (4.3)
2 (8.7)
2 (8.7)
0
5 (21.1)
3 (17.4)

.371
1.000
1.000
1.000
.109
.461
1.000

10 (43.5)
7 (30.4)
2 (8.7)
0
4 (17.4)
42.57 ± 14.6
217.65 ± 81.1

.060
.547
.234
.416
.416
.081
.244

51.74 ± 4.7
23.32 ± 1.5
4 (50.0)
7 (40.0)
0
1 (10.0)

(29.2)
(8.3)
(8.3)
(8.3)
(16.7)
(12.5)
(16.7)

4 (16.7)
10 (41.7)
0
8 (33.3)
2 (8.3)
50.13 ± 14.4
190.6 ± 76.0

pvalue

CVD without Enhancement: Patients referred for CMR not demonstrating LGE enhancement in
imaged slice. CVD with Enhancement: Patients referred for CMR demonstrating LGE
2
enhancement in imaged slice. BMI: Body Mass Index (kg/m ).
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Figure 2.1. 2-pt bSSFP Imaging Method.
(A-C) Representative data from a healthy control. End-diastolic reference
bSSFP images acquired with (A) 45° and (B) 5° flip angles provide MT-weighted
and proton density reference images, respectively. (C) Maps of ΔS/So that are
calculated from A and B demonstrate uniform and low values throughout the
heart. (D-F) Representative data from a patient without LGE-enhancement. Enddiastolic reference bSSFP images acquired with (D) 45° and (E) 5° flip angles.
This patient demonstrated no myocardial enhancement at LGE. (F) Map of ΔS/So
demonstrates uniformly low values similar to the healthy control. For all maps,
the color scale was chosen to emulate LGE imaging, with areas of
edema/fibrosis demonstrating signal enhancement and areas of healthy tissue
appearing dark.
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Figure 2.2. Identification of edema and necrosis in a patient with acute
myocardial infarction. (A) End-diastolic reference image of a midventricular
slice in which 2-point bSSFP, native T1-mapping, and LGE data were acquired.
(B) LGE imaging reveals an area of hyper-enhancement along the septum
indicative of edema and/or necrosis (red arrow). The corresponding maps of (C)
ΔS/So, and (D) native-T1 both demonstrate similar spatial patterns of elevated
values to LGE (red arrow). The corresponding T2-map and windowed bSSFP
image can be found in Figure 2.3.
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Figure 2.3. T2-Mapping and Weighting in Acute MI. (A) Anatomical reference
image from same patient as shown in Figure 2.2, with (B) corresponding LGE
image demonstrating area of edema following acute MI (red arrow). (C) T2mapping revealed focally and significantly elevated T2 in the area of acute MI,
corresponding to edema. (D). Significant contrast manipulation through window
and leveling of (A) reveals similar enhancement in the area of edema (red arrow),
however scattered noise is seen in areas outside of the enhanced area.
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Figure 2.4. Identification of scar tissue in chronic myocardial infarction. (A)
Magnitude reconstructed bSSFP image reveals a thinned wall along the inferior
right ventricular insertion point (red arrow). (B) LGE imaging confirms the
presence of primarily sub-endocardial scar tissue as an area of signal
enhancement (red arrow). Mapping of (C) ΔS/So and (D) native-T1 both reveal
increased values within the scar tissue (red arrows), and normal values
throughout the remaining myocardium.
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Figure 2.5. Two patients with non-ischemic dilated cardiomyopathy. (A, E)
Dilation of the left ventricle is present in both patients on end-diastolic images. In
the first patient, (B) no LGE-enhancement is present, (C) ΔS/So is normal
throughout the heart as is (D) native-T1. In the second patient, (F) mid-wall
septal LGE-enhancement is present (red arrows). (G) Heightened ΔS/So is
observed in close agreement with the LGE image (red arrows), however (H)
native-T1 values are elevated primarily at the right ventricular insertion-point.
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Figure 2.6. Tissue characterization parameters. (A) ΔS/So was significantly
elevated in tissue regions that enhanced on LGE images (Group IV) compared to
non-enhanced regions from the same patients (Group III), patients without any
LGE enhancement (Group II), and healthy controls (Group I). Similarly, (B)
native-T1 and (C) native-T2 were significantly elevated in tissue that enhanced
on LGE images compared to all other groups. (D) GPC was significantly higher in
tissue that enhanced on LGE images compared to non-enhanced tissue regions
in patients. (Lines represent p<0.05).
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Figure 2.7. Association of tissue characterization parameters with GPC. (A)
ΔS/So (R = 0.82), (B) native-T1 (R = 0.55), and (C) T2 (R = 0.75) all associated
strongly with GPC. Data points are shown for all measurements as either
enhanced on LGE images (white boxes) or non-enhanced on LGE images (black
diamonds).
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Figure 2.8. Association of enhanced area and transmurality between 2point bSSFP and LGE. (A) Comparison of the enhanced myocardial area
(represented as percent of total myocardial area) using 2-pt bSSFP and LGE
revealed a strong association between the two methods (R2 = 0.84) with a slight
bias towards larger areas of enhancement with 2-point bSSFP. (B) Bland-Altman
plot comparing the difference between enhanced areas by both methods to the
mean between both methods revealed a coefficient of covariance of 0.204. (C)
Similarly, the comparison of the transmurality of enhancement by each method
revealed a strong association between 2-point bSSFP and LGE (R2 = 0.73) with
(D) Bland-Altman analysis demonstrating a coefficient of covariance of 0.0875.
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Figure 2.9. False positive identification of enhancement at ΔS/So. (A-C)
Scattered noise on ΔS/So maps led to the false identification of diffuse
enhancement in 3 of the 4 false positive cases. A representative example of a
patient without enhancement at LGE (A) that was classified by blinded readers
as demonstrating diffuse enhancement at ΔS/So (B) in the septum with
corresponding anatomical reference image (C). (D-F) In one patient without
enhancement at LGE (D), focal enhancement (arrow) was identified on the
corresponding map of ΔS/So, with corresponding anatomical image shown in F.
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Figure 2.10. False negative identification at ΔS/So. All cases in which blinded
readers identified individuals with enhancement at LGE as normal at ΔS/So
occurred in cases of sub-endocardial enhancement. (A) Representative LGE
image from a patient with 50-75% sub-endocardial intermediate signal
enhancement (red arrows) in the inferior wall. (B) The corresponding map of
ΔS/So demonstrates elevated values in the same region (red arrows). (C) The
corresponding anatomical reference image confirms that the elevated ΔS/So
values in B occur in myocardial tissue.
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Figure 2.11. Simulations of changes in steady state signal intensity as a
function of T1, T2, and flip angle. (A) Using a T2 relaxation time of 48ms (the
mean amongst our healthy control cohort), and the TR and TE values from our
scanning protocol, simulations confirm that lengthening of T1 relaxation times
leads to a reduction in the steady state signal over a physiologically relevant
range of T1 relaxation times. (B) However, changes in T1 relaxation times in
fibrotic tissue are often accompanied by changes in T2 relaxation times that can
have the opposite effect on the steady state signal. For further simulation of the
steady state signal across a range of flip angles we examined healthy values
(blue) using the mean T1 (1022.2 ± 48.2 (ms)) and T2 (48.2 ± 2.3 (ms))
relaxation times from our healthy cohort and previously mentioned TR/TE and
proton density values. Separately, we simulated fibrotic tissue (red) using the
mean T1 and T2 relaxation times from tissues that enhanced at LGE in patients
that did not have acute-MI. This population included those with chronic MI and
patients with enhancement determined by our cardiologist to be non-ischemic in
origin. In this subset of patients (n = 12), the mean native-T1 relaxation time was
1125.6 ± 136.5 (ms), and the mean T2-relaxation time was 52.2 ± 7.7 (ms).
Examination of panel B demonstrates that decreases in steady state
magnetization due to increased T1 are partially mitigated by increased T2 in
fibrotic tissues. (C) The difference in steady state signal between the two
populations suggests that the contrast observed in maps of ΔS/So is likely heavily
influenced by changes in MT.

Copyright © Tori Ann Stromp 2016
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CHAPTER 3: MAGNETIZATION TRANSFER MAGNETIC RESONANCE
IMAGING IDENTIFIES CARDIAC FIBROSIS IN END STAGE RENAL DISEASE
WITHOUT GADOLINIUM AND CORRELATES WITH BIOMARKERS OF
COLLAGEN TURNOVER

Synopsis
Background: Patients with end stage renal disease (ESRD) suffer high rates of
cardiac mortality, likely from pervasive development of fibrosis. The
contraindication to gadolinium contrast agents prevents the use of late
gadolinium enhancement cardiac MRI (CMR) for fibrosis detection in ESRD,
although it is the clinical standard for cardiac tissue characterization. Measures of
hypertrophy or reduced strain are widely used as surrogates for fibrotic burden,
but are not specific to the development of fibrosis. We utilized our established
magnetization transfer-weighted technique, 2-point balanced steady state free
precession (2-pt bSSFP) for fibrosis identification and comparison with structure,
function, and biomarkers in patients with ESRD.

Methods: Patients on routine hemodialysis for ESRD (n=29) and healthy
controls (n=33) were imaged on a 1.5 T MRI using the 2-pt bSSFP CMR
technique. Myocardial ΔS/So was calculated as ΔS/So=(S5 – S45)/S5 *100 (%)
where Si is the signal intensity per flip angle i. Strain and strain rates were
measured in circumferential and longitudinal directions with a custom feature
tacking algorithm. A standard healthy distribution of ΔS/So signal was generated
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as a cumulative distribution function. The cumulative distribution of ΔS/So for
each participant was compared to the healthy standard. The difference between
cumulative distributions was integrated across the range of ΔS/So and the
resulting divergence value was used as a quantitative marker of fibrosis. Pearson
correlations were used to compare divergence to other widely used correlates of
fibrosis and blood biomarkers.

Results: Patients with ESRD were hypertrophic but with only slightly reduced
longitudinal strain compared to healthy controls. Mean ΔS/So and divergence
were elevated in patients with ESRD (144.7 ± 17.1% and 16.3 ± 14.3 AU
respectively) compared to controls (129.9 ± 12.0% and 6.5 ± 5.7 AU, p<0.01 for
both comparisons). Divergence was only moderately correlated with left
ventricular mass index (LVMI; rho=0.31, p<0.05) but did not correlate with strain
measures. Troponin T (TnT), fibroblast growth factor 23 (FGF23), and tissue
inhibitor of metalloproteinase (TIMP) 1 and 2 were elevated in the ESRD group
compared to controls. All of these biomarkers correlated with divergence, but
FGF23 and TnT also correlated with LVMI indicating that these biomarkers are
not specific enough to measure fibrosis alone. TIMP1 and 2 did not correlate with
hypertrophy or strain, suggesting that these matrix remodeling proteins may be
suitable for specific identification of fibrosis and may possibly serve as molecular
targets for future anti-fibrotic therapies.
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Conclusions: 2-pt bSSFP CMR in patients with ESRD revealed that solely using
hypertrophy or reduced mechanics as surrogate markers of fibrosis is
inappropriate. While biomarkers of ischemia (TnT) and remodeling (FGF23)
associated strongly with hypertrophy, they may lack specificity to cardiac fibrosis.
TIMPs may emerge as both a biomarker of extracellular remodeling and potential
therapeutic target specific to fibrosis in patients with ESRD.
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Background
Sudden cardiac death is a leading cause of death for patients who are on
routine hemodialysis for treatment of end stage renal disease (ESRD) [42].
Cardiac remodeling, which often manifests as hypertrophy in ESRD patients
[47,51], and/or the development of replacement or reactive fibrosis [58,59] can
lead to adverse cardiac events such as arrhythmia, heart failure, and eventually
death. ESRD hemodialysis patients are contraindicated to gadolinium contrast
agents [83], which are typically used for tissue characterization and fibrosis
imaging with cardiac magnetic resonance imaging (CMR). Subsequently, since
fibrosis and hypertrophy often occur in parallel, measurement of hypertrophy is
widely used as a surrogate for fibrosis. In other studies, specific blood
biomarkers including troponin T (TnT), fibroblast growth factor 23 (FGF23), and
parathyroid hormone (PTH), whose levels correlate well with the degree of
hypertrophy [141,142] are used as plasma biomarkers of fibrosis. Matrix
metalloproteinases (MMP) and tissue inhibitor of MMP (TIMP) are under
investigation as fibrosis specific markers in cardiomyopathy [143], heart failure
[36,144] and cardiorenal syndrome [145-148]. Measures of reduced diastolic
strain rate and global longitudinal strain (GLS) indicate stiffening of the left
ventricle (LV) in kidney disease patients [60], but may only be sensitive after
advanced fibrotic development. The currently employed surrogates of fibrosis—
hypertrophy, contractile function, and plasma biomarkers—are all indirect
measures and may not be directly correlated with the development of fibrosis as
a specific disease process in all patients with ESRD. Thus detecting cardiac
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fibrosis and linking it with measureable biomarkers in the ESRD population
remains both a challenge and a significant obstacle to the design and evaluation
of potential lifesaving therapies. Since fibrosis occurs simultaneously with the
expansion of interstitial space, two point balanced steady state free precession
(2-pt bSSFP) CMR, which is described in Chapter 2, is uniquely suited to
overcome the existing obstacles of studying cardiac fibrosis in patients with
ESRD.
In this study, we used 2-point bSSFP CMR in healthy controls and
patients with ESRD on routine hemodialysis for myocardial tissue
characterization. We then correlated measures of fibrosis with cardiac mechanics
and blood plasma biomarkers of remodeling that are purported to reflect
underlying fibrotic burden. We hypothesized that the magnitude of fibrosis will
correlate more strongly with the levels of markers of matrix turnover (MMPs and
TIMPs) than with the magnitude of hypertrophy, reduced strain, or levels of nonspecific biomarkers TnT and FGF23.

Materials and Methods
Participants and Recruitment
Patients on routine hemodialysis for ESRD were referred from the
University of Kentucky Nephrology Department and healthy volunteers were
recruited with assistance from the University of Kentucky Center for Clinical and
Translational Science and academic departments. All participants were
prospectively enrolled. Exclusion criteria included arrhythmia, inability to hold
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one’s breath, and standard MRI safety and compatibility concerns. Additional
exclusions for healthy volunteers were known cardiovascular disease,
hypertension, diabetes, obesity, and tobacco use. A total of 31 patients with
ESRD and 44 healthy controls were enrolled. Participants were excluded from
data analysis due to the inability to adequately hold their breath or complete the
MRI protocol (1 ESRD each) or for image quality concerns due to hardware
issues (5 healthy controls). BMI > 26 (n=4), abnormal ECG (n=1) or discovery of
aging related (n=1) or congenital abnormalities (n=1) in healthy controls were
additional grounds for exclusion in data analysis. The research protocol was
approved by the University of Kentucky Institutional Review Board and all
participants gave voluntary informed consent prior to participation.

Cardiac MRI Protocol
A 12 lead electrocardiogram (ECG) was conducted prior to the MRI to
detect arrhythmia or other electrical abnormalities. Participants were imaged on a
1.5T Siemens Aera scanner (Siemens Healthcare, Erlangen, Germany) using an
18 channel body coil and 12 channel chest coil and prospective ECG triggering.
A 4-chamber long axis cine image was acquired during localizers for assessment
of longitudinal strain. The 2-pt bSSFP method was completed as previously
described (Chapter 2). During end expiratory breath holds, cine bSSFP image
pairs were obtained at flip angles of 5° and 45° in a short axis stack, spanning
the LV from mitral valve to apex. Additional scanning parameters include TE: 1.2
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ms, TR: 3.2 ms, bandwith: 930 Hz, in plane spatial resolution: 1.02 x 1.02 mm,
slice thickness: 8 mm, GRAPPA 2.

Structure and Function Analysis
Left ventricular volumes and mass were analyzed using short axis images
in Argus Viewer (Siemens Healthcare, Erlangen, Germany). Left ventricular mass
index (LVMI) was calculated as mass at end diastole (g) indexed to body surface
area (m2). To characterize hypertrophy, H/R ratio was calculated at end diastole
in a mid-ventricular slice as H/R= septal thickness / ventricular radius (cm) similar
to Grossman, et al. [149]. Blood pressure data were collected post hoc from
electronic medical records, when available.

Strain Analysis
Circumferential and longitudinal strain and strain rates were assessed
using a custom feature tracking algorithm [150]. Endocardial borders were
manually defined and automatically segmented into 6 sectors (Figure 3.1).
Sectors were followed through the cardiac cycle using feature tracking and
manually corrected for errors in border definition. Peak strain was defined as the
maximum circumferential or longitudinal shortening from end diastole (%).
Circumferential strain was averaged across all short axis slices. Global
longitudinal strain was averaged across all endocardial sectors in 1 long axis
view. In each slice, average shortening across all sectors was plotted as a
function of the cardiac cycle. Systolic and diastolic strain rates were then defined
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as the minimum and maximum slopes during contraction and relaxation,
respectively (Figure 3.1).

Image Analysis
Offline image processing was conducted offline using MATLAB version
2014a (The MathWorks Inc., Natick, MA). Cine image pairs acquired at 5° (not
shown) and 45° (Figure 3.2 A and D) were assessed for misalignment and
manually adjusted to realign the left ventricular myocardium when necessary. 2pt bSSFP data was analyzed as previously described (Chapter 2). Maps of ΔS/So
(Figure 3.2 B and E) were generated for each slice location and each cardiac
phase using the formula ΔS/So=(S45-S5)/S5 x 100 (%), where Si is the signal
intensity per voxel at each flip angle i. To reduce random noise, 1 to 3 diastolic
ΔS/So maps without cardiac motion were averaged together when calculating
ΔS/So. The myocardium was manually defined on ΔS/So maps. Care was taken
to exclude voxels with partial volume averaging from blood pool and pericardial
fat. ΔS/So maps were automatically segmented into 6 sectors to calculate mean
values per sector. Bullseye plots are used to demonstrate mean ΔS/So per sector
across slices (Figure 3.2 C and F). Sectors are presented circumferentially, with
slices extending radially from apex (center) to base (exterior). Quantitative
analysis was completed using unfiltered ΔS/So maps. Figures are presented
using a 2x3 median filter.
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Quantification of Fibrosis
A standard distribution was defined by combining all myocardial ΔS/So
voxel values for all healthy participants in our study. To account for variations in
heart size, the standard distribution was dynamically resized to match the
number of voxels in each individual heart. For each participant, a cumulative
distribution function of ΔS/So values was compared against the appropriatelysized simulated distribution. A rightward shift in the distribution function occurs
when a greater proportion of voxels demonstrate increased ΔS/So values
consistent with tissue fibrosis. The difference between cumulative distributions
was integrated across the range of ΔS/So and the resulting value was used as a
quantitative marker of fibrosis termed divergence. An example of this analysis is
presented in Figure 3.2 G. Cumulative distribution analysis was limited to voxels
with 0-400% ΔS/So values to reduce the influence of potential region of interest
errors or additional random noise. These ranges span the expected values for
healthy, edematous, and fibrotic myocardium.

Blood Biomarker Analysis
In a subset of participants, blood samples were collected by standard
venipuncture and allowed to clot at least 30 minutes. Samples were centrifuged
at 1300g for 10 minutes at 4°C and stored at -80°C until analyzed with
commercially available assay kits. Serum concentrations of TnT were analyzed
by quantitative electrochemiluminescent immunoassay by ARUP Laboratories
(0098803, Salt Lake City, UT, USA). MMP2 and MMP9 were measured by
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enzyme-linked immunosorbent assay (ELH-MMP2, ELH-MMP9 ELISA; Ray
Biotech, Norcross, GA, USA). FGF23, PTH, TIMP1 and TIMP2 were analyzed by
Milliplex® magnetic bead panels (HBNMAG-51K, HTMP2MAG-54K; EMD
Millipore, Billerica, MA). Assays were run in duplicate and averages were used
for all analyses.

Statistical Analysis
Statistical results were computed using IBM SPSS Statistics Version 22
(IBM Corp, Armonk, NY). Shapiro-Wilk and Levene’s tests were used to assess
the normality and homogeneity of variance for all variables. Student’s t test or
Mann Whitney U tests were used where appropriate. Spearman correlations
were used to compare blood biomarkers against imaging results. Continuous
variables are presented as mean ± standard deviation or median [interquartile
range], where appropriate. Categorical variables are presented as count (%).
P<0.05 was considered significant for all tests.

Results
Twenty nine patients with ESRD and 33 healthy controls were included in
the study. Demographic characteristics are detailed in Table 3.1. Groups were
well matched in age and gender. Patients with ESRD had larger body mass
index compared to controls (<0.001). Hemodialysis vintage in patients with ESRD
was 4.8 ± 3.2 years. Six patients had prior kidney transplants that subsequently
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failed, requiring continuation of hemodialysis. Additional clinical features of the
ESRD group are described in Table 3.2.

Clinical Measures of Structure, Function, and Strain
Clinical measures from ECG and CMR are listed in Table 3.1. QRS
complex duration was similar between patients with ESRD and controls
(p=0.694), although 3 patients with ESRD had QRS duration longer than 120ms.
Corrected QT interval (QTc, normalized to 60 beats per minute) was longer in
patients with ESRD than controls (p<0.001). QTc was greater than 440ms in 18
patients with ESRD but only 6 healthy controls. The majority of patients with
ESRD had preserved ejection fraction with no differences between groups,
although 6 patients had EF below 55%. Mean LV mass was 112.5 ± 31.8g in
controls and 189.0 ± 65.1g in patients with ESRD (p<0.001). LVMI, septal
thickness, and H/R ratio were elevated in patients with ESRD compared to
controls (p<0.01 for all, see Table 3.1). There were no differences in strain
measurements between the ESRD and healthy control groups for circumferential
peak strain, systolic, or diastolic strain rates (Figure 3.3 A-C). Longitudinal peak
strain was slightly reduced in patients with ESRD (Figure 3.3 D) but did not reach
statistical significance. Longitudinal systolic and diastolic strain rates were similar
between groups (Figure 3.3 E-F).
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Tissue Characterization by 2-pt bSSFP
Representative ΔS/So maps from a healthy control (Figure 3.4) depict the
uniformly low ΔS/So values typical of healthy myocardium. An example patient
with ESRD is presented in Figure 3.5. This patient demonstrates diffuse
enhancements in ΔS/So, particularly towards the base of the LV. Importantly, if
this patient were to undergo myocardial tissue biopsy, the historical gold
standard for fibrosis detection where a small tissue sample is extracted from the
epicardial surface of the left ventricular septum at the mid-ventricle, the chance of
a false negative result would be high. The longitudinal position of the tissue
samples would impact the extrapolated whole-ventricle estimation of fibrotic
burden, which is actually highly varied across slices. Similar to Schietinger et al.
[59], we also found examples of 3 distinct patterns of fibrosis in patients with
ESRD (Figure 3.6), associated with both ischemic and non-ischemic origins.
From the ΔS/So maps generated at each short axis slice position, mean global
ΔS/So was calculated across the LV myocardium. Patients with ESRD had
significant elevation in global ΔS/So (144.7 ± 17.1%) compared to controls (129.9
± 12.0%, p<0.001, Figure 3.7 A). Divergence was also significantly increased in
the ESRD group (9.8 AU [6.0, 23.6]) compared to controls (4.7 A.U. [1.2, 11.5],
p=0.003, Figure 3.7 B), indicating a greater fibrotic burden in these patients.

Structure and Function Alterations are not Synonymous with Fibrosis
Representative examples of LV hypertrophy in the ESRD group are shown
in the anatomical cine images (α=45°) in Figure 3.8 A-D. While each of these
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example participants is considered hypertrophic, there is a wide range of fibrosis
patterns, indicated by elevated signal on corresponding ΔS/So maps (Figure 3.8
E-H). Spearman correlations were used to investigate the association of fibrosis
with hypertrophy, circumferential diastolic strain rate, and global longitudinal
strain (Figure 3.9). Moderate correlations were evident when comparing
divergence with LVMI (rho=0.31, p=0.014) and septal thickness (rho=0.27,
p=0.035), which are commonly utilized surrogate measures of fibrosis. No
correlation was found comparing divergence with diastolic strain rate (rho=0.06,
p=0.646) or global longitudinal strain (rho=0.02, p=0.910). LVMI correlated with
diastolic strain rate (rho=-0.26, p=0.043) and global longitudinal strain
(rho=0.383, p=0.002), indicating that increased hypertrophy was associated with
worsening relaxation and contraction. In patients with ESRD, hemodialysis
vintage was not correlated with divergence (rho=-0.164, p=0.395), indicating that
length of time on hemodialysis is also not a good indicator of fibrotic burden.

Blood Biomarkers and Correlations with LV Remodeling
We collected blood samples from a subset of healthy controls (n=25) and
patients with ESRD (n=16). Serum concentrations of blood biomarkers are
detailed in Table 3.3. The typical biomarkers of ischemia and cardiac remodeling,
TnT and FGF23, were elevated in patients with ESRD (Figure 3.10 A-B), as was
PTH. Markers of extracellular matrix turnover, TIMP1 and TIMP2 were also
elevated in the ESRD group (Figure 3.10 C-D). Correlation analysis with
divergence revealed moderate associations between fibrosis and TnT (rho=0.32,
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p=0.043), PTH (rho=0.33, p=0.035), TIMP1 (rho=0.39, p=0.013), and TIMP2
(rho=0.40, p=0.011) but not FGF23 (Figure 3.10 E-H). Interestingly, TnT
(rho=0.59, p<0.001), FGF23 (rho=0.343, p=0.030), and PTH (rho=0.37, p=0.019)
also correlated with LVMI while TIMP1 and 2 did not. These overlapping
correlations reveal the complex interaction between hypertrophy and fibrosis,
while indicating that TnT, FGF23, and PTH may not be suitable for fibrosis
detection in patients with ESRD.

Discussion
Reactive and replacement patterns of fibrosis have been previously
identified in patients with ESRD using gadolinium [58,59]. Due to the risk of
nephrogenic systemic fibrosis [151], patients with ESRD are now excluded from
MRI examinations with gadolinium. Without the availability of safe and
noninvasive fibrosis measurement techniques, surrogate measures such as
hypertrophy or reduced contractility are widely used to estimate fibrotic burden
for diagnostic, prognostic, and treatment efficacy purposes. In this study, we
utilized 2-pt bSSFP, a magnetization transfer contrast CMR technique, to
characterize myocardial fibrosis without the need for gadolinium in patients on
routine hemodialysis for ESRD. We used quantitative evidence of fibrosis to
challenge the current prevailing view that using hypertrophy or reduced
contractility are accurate surrogates for fibrosis measurements.
ΔS/So values in healthy, age-equivalent controls agreed with our prior data
using 2-pt bSSFP (Chapter 2, Figure 2.6). We demonstrated elevated myocardial
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ΔS/So in patients with ESRD, corresponding to increased interstitial fibrosis and
decreased magnetization transfer. Signal elevation is evident upon subjective
inspection of ΔS/So maps (Figure 3.5, Figure 3.8) and with quantitative analysis
of the distributions of ΔS/So (Figure 3.7). While greater than healthy tissue, mean
ΔS/So values over the LV in patients with ESRD fell below focal values for tissue
that enhanced at LGE from our previous study (Chapter 2). This is expected due
to the propensity for a diffuse pathology in patients with ESRD.
Our patients with ESRD demonstrated prolonged QTc with 18 patients exceeding
the standard normal cutoff of 440ms. Lengthened QT times may be
demonstrative of increased ventricular fibrosis which can slow conduction times
[38]. Prolonged QT is associated with the development of ventricular arrhythmia,
specifically torsades de pointes [152], and is associated with mortality and
sudden cardiac death in patients hemodialysis [153,154]. In addition to fibrosis,
severe alterations in electrolytes may predispose patients on hemodialysis to
development of arrhythmia [49,154] and time since last treatment may impact
ECG recordings [154]. These confound make the detection of fibrosis a complex
task by ECG alone.
Since fibrosis can lead to ventricular stiffening [35,36], strain
measurements by echocardiography [165] and CMR [60] have been used to
estimate fibrosis in patients with ESRD. However, the drastically fluctuating
hemodynamics in patients receiving hemodialysis modify echocardiographic
measures [52,68], which may not actually associate with histological measures of
fibrosis in this population [51]. Strain measurements correlated with hypertrophy
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but not fibrosis in this study, indicating that measures of ventricular stiffness may
be a consequence of thickened LV walls and not specifically the development of
fibrosis.
Previous reports indicate a varied but large proportion—up to 91%[55]—of
hemodialysis patients with hypertrophy [56-58]. Hypertrophy is associated with
emergence of cardiovascular disease and death in the general population [17,18]
and with poorer prognosis in patients with hypertension[155], aortic
stenosis[156], heart failure with preserved ejection fraction [157], and ESRD [58].
Indeed, our findings confirmed that hypertrophy was prevalent among individuals
with ESRD. However, using MRI strain imaging, which is more accurate and
reproducible than comparable ultrasound based methods, we observed only
slightly reduced longitudinal contraction compared to healthy, age-equivalent
controls (Table 3.1,Figure 3.3). Though hypertrophy is prognostic, it does not
differentiate the etiology of adverse cardiac outcomes such as development of
interstitial fibrosis leading to fatal arrhythmias. As described in our study,
hypertrophy only moderately associated with divergence (Figure 3.9) and may
not be an appropriate surrogate to detect fibrosis or probe for biomarkers specific
to fibrosis. In fact, others have shown a lack of correlation between hypertrophy
and fibrosis in patients with kidney disease [60] and demonstrated that fibrosis is
an independent risk factor for cardiovascular mortality in ESRD above and
beyond hypertrophy or contractile dysfunction [51].
Investigations of molecular mechanisms of remodeling have identified
FGF23 [141,158,159], PTH [142,159,160] and serum phosphates [158,159] as
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potential factors driving ventricular hypertrophy. Specifically, FGF23 is correlated
with LV hypertrophy [53,141] and linked to increased risk of cardiac mortality in
patients with ESRD [141,142,158]. Emerging therapies seeking to abrogate
effects of elevated serum FGF23 levels through dietary intervention [53,158,161],
oral phosphorous binder therapy [53,158] or use of lanthanum carbonate [162],
are promising for the reduction of serum FGF23 levels over time. However, prior
studies have demonstrated that phosphate binder and vitamin D therapies
[141,163], and even renal transplantation [164] fail to reverse left ventricular
hypertrophy, despite improving outcomes [161]. FGF receptors that are normally
only activated after myocardial infarction to promote formation of fibrotic scar
tissue may be activated by excess FGF23 [53], suggesting that fibrotic
remodeling may play a greater role in promoting adverse cardiac events in ESRD
patients. This view is substantiated by extensive interstitial fibrosis measured by
biopsy [51] and LGE CMR [58,59], prior to its contraindication in ESRD patients,
along with the link for cardiac fibrosis to promote arrhythmia [62], heart failure,
and sudden death. In fact, increased fibrotic burden is associated with worse
prognosis and predicts sudden cardiac death independent of hypertension,
diabetes, ejection fraction, LV dilation, and cardiomyocyte hypertrophy in patients
with ESRD [51].
Translational and early clinical trials show promise for the cardiac benefits
of emerging therapies such as spironolactone [166,167], galectin 3 blockade
[168], and FGF23 blockade [141,169] but with outcome measures of reduced
hypertrophy, improved contraction, or decreased cardiac death. Cardiac fibrosis
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has been attenuated in animal models of pressure overload hypertrophy treated
with spironolactone [170] and dilated cardiomyopathy [171] and renal failure
[172] treated with rapamycin. In patients with ESRD, the progress of these and
other potentially lifesaving treatments is limited by the reliance on hypertrophy or
reduced contraction for disease monitoring. While hypertrophy and fibrosis are
interrelated, if patients are diagnosed and selected based only on hypertrophy or
contractile status for clinical trials whose outcomes only measure improvements
in structure or strain, the entire fibrotic disease process is overlooked. It is
imperative for the design and development of targeted anti-fibrotic therapies to
rely on the accurate detection of fibrosis and specific molecular mechanisms in
the context of ESRD and hemodialysis, otherwise new therapeutics may
effectively treat hypertrophy or contraction without affecting the independent
development of fibrosis.
The patients examined in this study demonstrated significantly elevated
TnT, FGF23, PTH, TIMP1, and TIMP2, reduced MMP9 and a trend toward
elevated MMP2 compared to healthy controls (Table 3.3). While each of these
biomarkers may indicate generic risk of arrhythmia or cardiac death, there is a
complex interaction between hypertrophy and fibrosis that is not distinguished by
these biomarkers. In fact, we found correlations with both hypertrophy and
fibrosis for TnT, FGF23 (Figure 3.10 E-F) and PTH, indicating that none of these
are specific enough to detect fibrosis alone.
MMPs play a crucial role in degrading the existing extracellular matrix, for
example, in acute myocardial infarction to allow infiltration of inflammatory cells
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to clear necrotic myocytes and initiate the healing process [173]. MMP2 and 9,
which comprise the gelatinases, primarily degrade denatured collagen, but may
also have a pro-fibrotic role in the heart [174]. TIMPs 1 and 2 are the most widely
investigated inhibitors of MMPs. TIMPs bind the catalytic domain of MMPs in a
1:1 fashion, thereby preventing degradation of MMP substrates [175].
Independent of MMP interactions, TIMPs have alternative signaling roles, which
can result in increased cardiac fibroblast proliferation and activation, and
therefore collagen synthesis [176]. The balance between MMP and TIMP ratio is
crucial for maintaining proper extracellular matrix form and function. For these
reasons, MMPs and TIMPs have been investigated as molecular mechanisms of
cardiac remodeling and fibrosis, and the subsequent link with contractile
dysfunction in non-diseased aging populations [22] as well as hypertrophic
cardiomyopathy [143], overload induced hypertrophy [177], myocardial infarction
[173,178], hypertension [179], and heart failure [144]. MMPs and/or TIMPs may
not only serve as prognostic or diagnostic markers, but pharmaceutical targets
for adverse structural or fibrotic remodeling. A promising study in a murine model
of experimental myocardial infarction demonstrated the beneficial effects of
inhibiting MMP2 and MMP9 by doxycycline, an FDA approved antibiotic [180].
MMPs and TIMPs have been investigated as cardiac biomarkers in
hemodialysis patients, with conflicting results [146,148,181,182] but with the goal
of being easily measured parameters for non-invasive myocardial tissue
characterization [183]. We have shown that patients with ESRD not only
demonstrate elevated circulating TIMP1 and TIMP2, but that both of these
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biomarkers correlate with measures of fibrosis, independent of hypertrophy
(Figure 3.10 G-H). Importantly, it has been shown that MMPs and TIMPs are
elevated in patients with deteriorating heart failure, but not end stage heart failure
or normal function [144]. Thus, MMPs and TIMPs may be important indicators of
cardiac disease progression, possibly through development of fibrosis. Future
investigations are warranted to understand cardiac remodeling processes, tissue
characterization, and MMP/TIMP involvement in hemodialysis patients, while
taking into account the effects of hemodialysis treatment on the circulating
concentrations of biomarkers [147,148].
Efforts to image myocardial fibrosis without gadolinium are currently under
investigation, with the goal of applying non-contrast CMR to patients with kidney
failure or other contraindications to gadolinium. Mapping of native T1 relaxation
times [88,89] has shown promise for tissue characterization in cardiomyopathy
[95,97], aortic stenosis [94], and Anderson-Fabry disease [104]. Recently, native
T1 mapping has been applied to patients with ESRD [90,99,184]. Graham-Brown
et al. demonstrated globally elevated T1 times as well as diffuse and nonischemic, focal fibrosis patterns [184], similar to a previous report using LGE
CMR [59] and to our results shown in Figure 3.6. The patients included in that
study demonstrated reduced contractility, indicating that this sample may have
had established heart failure and more advanced fibrosis compared to our
patients, although the differences in T1 maps are visually subtle. Importantly,
unless corrected for hematocrit, T1 times may be erroneously elevated due to
anemia caused by hemodialysis and may vary depending on time since last
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treatment. T1 mapping sequences are also commonly sensitive to elevated and
variable heart rates, particularly for longer T1 times [91], which all routinely occur
in individuals with ESRD.
A few important limitations are relevant to this study. Since 2-pt bSSFP
imaging requires 2 consecutive end-expiratory breath holds, patient motion and
breath hold variation between acquisitions may limit this technique. We manually
registered any misaligned image pairs to adjust for inaccurate position. While this
could introduce additional human error and noise in the ΔS/So maps, many slices
were salvaged for data analysis that would otherwise be excluded from this
study. While we are currently unable to collect low and high MT-weighted images
simultaneously in a single breath hold, future investigations will aim to reduce
table time and patient fatigue, while optimizing MT-weighting sequences to
reduce analytical limitations.
Regions of interest were carefully defined to include only myocardial
voxels, however it is possible that some voxels with partial volume effects from
the blood pool or pericardial fat were included in our analyses. These erroneous
voxels are more likely to be included for healthy controls since the myocardium is
often thinner than in patients with ESRD. Thus, our calculation of ΔS/So may be
slightly elevated in controls and true group differences may be greater than what
we described. To eliminate the impact of this noise, in quantitative analysis we
restricted the range of voxel values to 0-400% for ΔS/So which incorporates the
expected physiologic ranges for normal and fibrotic myocardium.
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In conclusion, we have shown that endogenous contrast mechanisms can
be measured in the myocardium of patients with ESRD using 2-pt bSSFP CMR.
MT-weighted CMR identifies increased fibrosis in patients with ESRD, which only
moderately associated with hypertrophy but not systolic or diastolic dysfunction.
The accuracy of imaging-guided biomarkers such as TIMP1 or 2 will benefit from
the capacity to delineate between hypertrophy and fibrosis and may serve as
potential therapeutic targets for future therapies to attenuate fibrosis in patients
on hemodialysis for ESRD. Accurate and safe measurement of fibrotic burden
and distribution could inform appropriate pharmaceutical interventions or serve
as selection criteria for alternative treatments such as radiofrequency ablation
and implantable cardioverter-defibrillator to prevent arrhythmias and ultimately
reduce the risk of sudden cardiac death in patients with ESRD. We have
challenged the dogmatic view that degree of hypertrophy or contractility directly
represents fibrotic burden and have offered a non-contrast imaging solution to
specifically measure LV fibrosis in patients with ESRD.
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Table 3.1. Participant Characteristics.
Healthy Controls Patients with ESRD
(n=33)
(n=29)

Variable

Demographics
Age (yrs.)
54.0 ± 10.9
53.7 ± 12.8
Male
15 (45)
14 (48)
White/Caucasian
29 (88)
16 (55)
Black/African American
1 (3)
12 (41)
Asian
0
1 (3)
American Indian
1 (3)
0
Hispanic
2 (6)
0
2
Body Mass Index (kg/m )
24.2 ± 2.3
31.6 ± 6.8†
Cardiac Structure and Function
Left Ventricular Mass Index (g/m2)
60.4 ± 13.3
94.3 ± 27.8†
Septal Thickness (cm)
0.9 ± 0.2
1.3 ± .03†
H/R Ratio
0.3 ± 0.1
0.5 ± 0.2†
End Systolic Volume (mL)
34.5 [25.3, 46.0]
36.5 [31.5,54.4]
End Diastolic Volume (mL)
92.3 ± 25.3
116.5 ± 41.0*
Ejection Fraction (%)
60.5 [56.0, 64.4]
63.8 [58.4, 68.1]
Heart Rate (bpm)
60.8 ± 8.8
72.3 ± 10.8†
QRS Duration (ms)
90.0 [84.0, 98.0]
94.0 [77.0, 104.0]
QTc interval (ms)
422.7 ± 18.4
463.0 ± 37.7†
Cardiac Mechanics
Global Diastolic Strain Rate (%/s)
174.1 ± 33.9
162.8 ± 41.7
Global Longitudinal Strain (%)
-21.8 [-26.0, -20.1] -20.9 [-23.3, -18.7]*
Continuous variables are presented as mean ± standard deviation or median
[interquartile range]. Categorical variables presented as count (%).*p<0.01, †p<0.001
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Table 3.2. Clinical Features of Patients with ESRD.
Clinical Features
Results
Dialysis Duration (years)
4.8 ± 3.2
Primary Etiology of End Stage Renal Disease
Diabetes
12 (41)
Hypertension
7 (24)
Glomerulonephritis
2 (7)
Reflux Nephropathy
2 (7)
Obstructive Nephropathy
1 (3)
Interstitial Nephritis
1 (3)
Focal Segmental Glomerulosclerosis
1 (3)
Unknown
3 (10)
Comorbidities
Hypertension
27 (93)
Diabetes
17 (59)
Prior Myocardial Infarction
4 (14)
Continuous variable is presented as mean ± standard deviation.
Categorical variables are presented as count (%).
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Table 3.3. Blood Biomarker Results
Healthy Controls
Patients with ESRD
p
(n=25)
(n=16)
<0.001
TnT (ng)
undetected
0.05 [0.0, 0.18]
0.001
FGF23 (pg)
0.00 [0.00, 0.00]
521.22 [29.47, 1210.85]
<0.001
PTH (pg)
139.66 [78.45, 167.61]
544.20 [340.78, 901.96]
0.051
MMP2 (ng)
11.21 [6.89, 20.08]
23.02 [11.88, 33.35]
0.026
MMP9 (ng)
931.90 [643.31, 1201.70]
552.53 [347.87, 718.14]
0.005
TIMP1 (pg)
4336.00 [4090.50, 5757.50] 6371.00 [4323.00, 7567.00]
0.035
TIMP2 (pg)
3255.00 [2555.50, 4408.50] 4676.00 [2953.00, 5302.00]
TnT: troponin T, FGF: fibroblast growth factor, PTH: parathyroid hormone, MMP:
matrix metalloproteinase, TIMP: tissue inhibitor of MMP. Values are presented as
median [interquartile range]. p< 0.05 was considered significant by analysis with
Mann-Whitney U test.

Variable
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Figure 3.1. Cardiac mechanics analysis in a healthy control. (A) In each
transverse slice, endocardial borders were manually defined at end diastole and
automatically followed through the cardiac cycle using a feature tracking
algorithm. (B) Average circumferential shortening across all sectors was plotted
as a function of the cardiac cycle (grey lines), and diastolic strain rate was
calculated as the maximum slope during relaxation (red line), which was
120.32%/sec for this participant. (C) Similarly, longitudinal strain as a function of
cardiac phase was calculated from a 4 chamber longitudinal cine image. (D) The
peak global longitudinal strain was defined by the maximum shortening value
(arrow), which in this participant was 17.4%.
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Figure 3.2. Two-pt bSSFP technique and quantitative analysis. (A) A cine
bSSFP image at α=45° in a representative healthy control was paired with an
image with α=5° (not shown). Maps of ΔS/So were generated as ΔS/So=(S45S5)/S5 x 100 (%), where Si is the signal intensity per voxel at each flip angle i. (B)
A ΔS/So map from this healthy control demonstrates low and uniform ΔS/So
values in a mid-ventricular slice. (C) Low ΔS/So is evident across all slices and
sectors of the heart in a whole-heart bullseye plot representing mean ΔS/So per
sector in this control. (D) A mid-ventricular image taken at α=45° from a
representative patient with ESRD and (E) the corresponding ΔS/So map, with
noticeable elevated signal intensity. (F) Elevated values are present throughout
the ventricle, as seen in the bullseye plot. (G) Using all LV myocardial ΔS/So
values from the control group, a simulated cumulative distribution function was
generated (black). The simulation was dynamically resized to match the number
of voxels per heart and compared to the cumulative distribution function of
observed ΔS/So values for each individual ventricle. Cumulative distributions from
the healthy control in b (orange) and patient with ESRD in e (red) are shown. We
integrated the area between the simulation and each participant’s distribution
(here, the patient from E) to define the divergence (gray) in ΔS/So. Divergence is
a metric of fibrotic burden.
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Figure 3.3. Relaxation was preserved and contractility was slightly reduced
in patients with ESRD. (A) Circumferential peak strain, (B) systolic strain rate,
and (C) diastolic strain rate were similar between groups (all p>0.05). (D) Global
longitudinal strain was slightly reduced in patients with ESRD (-20.5 ± 4.1%)
compared to controls (-22.9 ± 3.5%, p=0.035), while (E) longitudinal systolic and
(D) diastolic strain rates were not different (p>0.05 for both). A large overlap in
values indicates that global longitudinal strain is not a robust, independent
predictor of increased fibrotic burden. Gray bars indicate group means. *p<0.05.
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Figure 3.4. Representative images from a healthy control. In a
representative healthy control, ΔS/So maps from base (top left) to apex (bottom
right) reveal uniformly low myocardial signal throughout the LV. Low ΔS/So is
consistent with healthy myocardial tissue.
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Figure 3.5. Representative images from a patient with ESRD and moderate
fibrosis. ΔS/So maps from base (top left) to apex (bottom right) in an example
patient with ESRD with moderate diffuse fibrosis. The LV was noticeably
hypertrophied with scattered ΔS/So enhancement, indicating diffuse fibrosis,
particularly in basal slices. This example demonstrates the need for accurate
fibrosis mapping across the entire LV, since fibrosis burden and pattern changes
drastically from base to apex of the LV.
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Figure 3.6. Recapitulation of three prevailing patterns of fibrotic tissue in
renal failure patients. Prior to the FDA warning and contraindication of
gadolinium, Schietinger et al.[59] observed 3 dominant patterns of late
gadolinium enhancement in renal failure patients: (A) thin scar like enhancement,
(B) diffuse subendocardial fibrosis, and (C) focal fibrosis at the ventricular
insertion points unrelated to ischemia. (A-C adapted from [59].) MT-weighted
fibrosis in renal failure patients imaging reveals similar patterns to those seen
previously using late gadolinium enhancement MRI. (D-F) End diastolic bSSFP
images in 3 renal failure patients and corresponding maps of ΔS/So reveal (G)
thin enhanced tissue , (H) diffuse enhancement, and (I) focal enhancement at the
ventricular insertion point.
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Figure 3.7. Patients with ESRD had increased signal intensity and fibrotic
burden. (A) Whole-ventricle ΔS/So values were significantly elevated in patients
with ESRD (144.7 ± 17.1%) compared to controls (129.9 ± 12.0%, p<0.001). (B)
Divergence was increased in patients with ESRD (16.3 ± 14.3) compared to
controls (6.5 ± 5.7 AU, p=0.003), indicating a greater fibrotic burden. Gray bars
denote group means. *p<0.01, †p<0.001.
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Figure 3.8. Patients with ESRD were hypertrophic but displayed a variety of
fibrosis patterns. (A-D) Representative mid-ventricular images (α=45°) from 4
individual patients with ESRD who displayed hypertrophy, particularly in the
interventricular septum. (E-H) Corresponding ΔS/So maps from the patients in ad demonstrated a wide range of signal elevation in these patients, indicating that
hypertrophy alone is not a good predictor of fibrotic burden in patients with
ESRD.
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Figure 3.9. Fibrosis moderately associated with hypertrophy but did not
correlate with strain. (A) Left ventricular mass index (LVMI) demonstrated a
moderate correlation with divergence (rho=0.31, p=0.01). Notably, the correlation
between LVMI and divergence was not linear. Patients with the highest values of
either variable did not regularly demonstrate the highest values in the other. (B)
Neither diastolic strain rate nor (C) global longitudinal strain correlated with
divergence (p>0.05 for both).
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Figure 3.10. Patients with ESRD had elevated blood biomarkers with
moderate correlations to fibrosis. Patients with ESRD demonstrated elevated
concentrations of (A) troponin T (TnT), (B) fibroblast growth factor (FGF) 23, (C)
tissue inhibitor of metalloproteinase (TIMP) 1 and (D) TIMP2. See Table 3.3 for
complete biomarker results. (E) Spearman correlation analysis revealed a
moderate association between divergence and TnT (rho=0.32, p=0.04). (F)
FGF23 did not correlate with divergence (p=0.12). (G) TIMP1 and (H) TIMP2
demonstrated a moderate correlation with divergence (rho=0.39, p=0.01 for
each). *p<0.05, †p<0.01, ‡p<0.001.
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CHAPTER 4: LONGITUDINAL MONITORING OF CARDIAC FIBROSIS
PROGRESSION USING MAGNETIZATION TRANSFER CARDIAC MRI IN
PATIENTS ON HEMODIALYSIS FOR END STAGE RENAL DISEASE

Synopsis
Background: Chronic hemodialysis treatment is associated with a timedependent increased risk of cardiac mortality, up to 20 times greater than the
general population. Ventricular fibrosis may be a leading cause of higher death
rates, yet the exclusion from gadolinium enhancement cardiac MRI (CMR)
excludes patients with end stage renal disease (ESRD) from noninvasive fibrosis
identification. Progressive hypertrophy and ventricular stiffness are currently
utilized as alternate measures of fibrotic burden but are more likely measures of
structural and functional alterations irrespective of the development of fibrosis.
We employed our non-contrast, 2 point balanced steady state free precession (2pt bSSFP) CMR technique to test the hypothesis that fibrosis progresses over 1
year in patients with ESRD independent of any changes in hypertrophy or
contractility.

Methods: Patients on routine hemodialysis for treatment of ESRD who
completed our previous study were invited to participate in a follow up 1 year
later. ΔS/So and strain were calculated using our standard techniques. Using the
healthy standard distribution of ΔS/So established in our prior study, we
compared cumulative distributions of ΔS/So acquired in follow up scans to
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calculate divergence, a metric of fibrotic burden. Measures of structure, function,
and fibrosis were compared between the 2 time points with paired t tests.

Results: Six patients completed follow up 2-pt bSSFP imaging. All patients were
hypertrophic at baseline but demonstrated minimal alterations in hypertrophy
over time. Changes in circumferential and longitudinal strain were varied, but not
significantly altered from baseline. ΔS/So and divergence were considerably
increased at follow up by an average of 10.3 ± 16.0% and 7.1 ± 13.7% AU,
respectively.

Conclusions: Patients with ESRD did not demonstrate significant changes in
hypertrophy nor contractility over a 1 year follow up period. The phenotypes of
fibrosis progression were varied, which demonstrates the heterogeneous
development of fibrosis in this population and the need for fibrosis specific
monitoring independent of structural and functional alterations. Non contrast
fibrosis imaging may serve as a better prognostic tool than the current
alternatives of hypertrophy and stiffness, aiding in more appropriate monitoring
and treatment selection for patients with ESRD.
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Background
One in 4 patients on hemodialysis for treatment of end stage renal disease
(ESRD) will die from sudden cardiac death [44]. For long term hemodialysis
patients (up to at least 6 years), risk of cardiovascular mortality is 10-20 times
greater than the general population [47]. Over the last 30 years, post-mortem
histological studies have repeatedly established high prevalence of cardiac
fibrosis in deceased ESRD patients [55,58,59]. It is now appreciated that the
progressive development of cardiac fibrosis is associated with increased risk of
arrhythmia [69], heart failure [64], and sudden cardiac death in ESRD [51].
Cardiac fibrotic burden may be correlated with time on dialysis [55] while cardiac
death rates increase steadily over multiple years of treatment [185].
Patients with ESRD are excluded from late gadolinium enhancement
(LGE) cardiac magnetic resonance imaging (CMR) due to the risk of developing
nephrogenic systemic fibrosis [186]. The inability to noninvasively visualize and
monitor fibrosis progression impedes the ability to develop and test targeted
treatments for the attenuation of cardiac fibrosis in this high risk population.
Visually and quantitatively monitoring cardiac fibrosis over time has applications
for clinical trials of anti-fibrotic therapies such as spironolactone [170,187] or
fibroblast growth factor receptor blockade [141,188] as well as patient selection
for pharmaceutical intervention, radiofrequency ablation, or implantable
cardioverter-defibrillator placement. Collagen volume fraction from myocardial
tissue biopsy has been the historical gold standard for detecting and quantifying
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fibrosis but is prone to false negatives [65] and is undesirable for serial
measurements.
Over years of hemodialysis treatment, patients with ESRD have an
increasing risk of cardiac mortality [185], which may be due to advancing fibrosis.
We hypothesized that over 1 year, cardiac fibrosis progresses in patients on
routine hemodialysis for treatment of ESRD, irrespective of structure or function
alterations. Chapter 3 described a baseline study of fibrosis identification using
our 2-pt bSSFP method (described in Chapter 2) in patients with ESRD. Here we
report a 1-year follow up study conducted in a subset of these patients with
ESRD. We measured the progression of left ventricular (LV) fibrosis using 2-pt
bSSFP along with structural and functional correlates of heart failure.

Materials and Methods
Participants
All patients with ESRD from our previous study (Chapter 3) were invited to
return for a second study visit 1 year after their initial scan. Participants were
considered eligible for this follow up study if they were presently on hemodialysis
treatment, had no MRI-unsafe implants or devices and had not developed
arrhythmia (for proper ECG gating of sequences). This study was approved by
the local Institutional Review Board and all participants were consented for the
initial study and re-consented for the follow-up, if necessary. Since this was a
repeated measures design, each patient served as his/her own internal control,
thus reducing variability and increasing statistical power.
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Cardiac Imaging Protocol and Image Analysis
All baseline characteristics were collected during the initial visit for
completion of this prior study and reported in this chapter only for patients who
participated in the follow up study visit. All cardiac imaging and offline image
analysis including structure, function, and strain was completed exactly as
described in Chapter 3: Materials and Methods. All quantitative analysis was
completed on raw data from ΔS/So maps. Figures are displayed using a 2x3
median filter to reduce noise. We used the healthy standard cumulative
distribution function generated from healthy controls in the initial study (Chapter
3) as the reference standard for analysis of ΔS/So signal enhancement in follow
up images. Thus, both baseline and follow up scans were compared against the
same healthy standard distribution for the calculation of divergence, as a metric
of fibrotic burden.

Statistical Analysis
IBM SPSS Statistics Version 22 (IBM Corp, Armonk, NY) or MATLAB
(MathWorks Inc., Natick, MA) were used to complete all statistical analyses.
Paired t-tests were used to compare baseline and follow up measures. Data are
presented as mean (range) or count (%) where appropriate. All comparisons
were considered significant at the p<0.05 level.
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Results
Patient Characteristics
From the initial study, 11 patients were eligible to complete a 1-year follow
up scan. Of these, 1 patient had received a kidney transplant and discontinued
dialysis and 4 others declined to participate for medical or other reasons. Six
patients completed follow up CMR visits for this study. Demographic information
is detailed in Table 4.1. Primary cause for kidney failure was hypertension (50%),
diabetes (33%) or unknown (17%). All 6 patients were concurrently hypertensive
and 4 patients (67%) had Type 2 diabetes. One patient had a failed kidney
transplant and subsequently started hemodialysis, prior to the baseline scan.
Average time on hemodialysis was 4.5 years at baseline. All participants
completed the follow up CMR visit approximately 1 year after the initial visit
(average=12.3 months since baseline, range: 11.1-14.4 months).

Clinical Cardiac Measures of Structure, Function, and Strain
Clinical features at baseline and follow up are detailed in Table 4.2.
Neither body mass index (BMI) nor body surface area (BSA) was significantly
changed. On ECG, corrected QT (QTc) interval shortened from 487.5 ± 36.4 ms
to 439.2 ± 11.3 ms (p<0.05). End diastolic volume (EDV) did not change, but
there was a trend toward reduced end systolic volumes (from 56.7 ± 26.6 mL to
47.747 ± 25.0 mL, p=0.053) which contributed to increased ejection fraction (EF)
from 61.2 ± 8.8% to 65.9 ± 10.4% (p=0.044) over the follow up period. Average
LV mass, LVMI, septal thickness, and H/R ratio were not significantly changed
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over the follow up year (Figure 4.1), although 5 of the 6 patients demonstrated
slightly reduced EDV, reduced ESV, and increased EF (Table 4.2). While this
cohort was hypertrophic at baseline, as a group, LV mass did not significantly
increase over the follow up period and H/R ratio decreased slightly. Between
baseline and follow up, changes in circumferential diastolic strain rate (from 174.
3 ± 45.9%/s to 177.2 ± 52.9%/s, p> 0.05) and longitudinal strain (from -20.6%/s
to -21.5%, p>0.05) were varied, but not significantly different (Figure 4.2).

Examples of Fibrosis Development
Among the six individuals recruited to date for a 1-year follow up scan,
diverse phenotypes were observed with respect to progressive changes in the
magnitude of cardiac fibrosis. Some patients demonstrated low levels of ΔS/So at
baseline with progressively increased ΔS/So over time, which is seen in Figure
4.3. This example patient had received hemodialysis treatment for approximately
2 years at baseline. Low and uniform ΔS/So values are seen across the LV in
baseline images (Figure 4.3 A-C). Globally, this patient demonstrates normal
baseline ΔS/So values throughout the entire myocardium in line with those
established for healthy controls in Chapter 3 (Figure 4.3 D). At the time of the
follow up visit, diffusely elevated ΔS/So values were evident across the 3 example
slices (Figure 4.3 E-G) primarily in basal and septal regions of the heart (Figure
4.3 H). Divergence increased from 9.8 AU (within the bounds of healthy controls)
to 27.6 AU (well outside the range of normal values), indicating advanced fibrosis
progression in this patient.
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In contrast to the prior individual, some patients who were imaged
demonstrated negligible alterations in ΔS/So during the follow up period. Baseline
scans from another representative patient on hemodialysis (4.3 years) reveal low
and uniform ΔS/So in example slices (Figure 4.4 A-C) and across the entire LV
(Figure 4.4 D). In follow up images (Figure 4.4 E-G), minimal ΔS/So elevations
are detected, mainly in the mid ventricle but not elsewhere throughout the LV
(Figure 4.4 H). A small increase of 3.9 AU in total LV divergence demonstrates
the minor progression of fibrosis in this patient.

Longitudinal Monitoring of Fibrosis Progression
Five patients demonstrated increased ΔS/So (Figure 4.5 A) and
divergence values (Figure 4.5 B) with an average group increase of 7.1 ± 13.7
AU in divergence from baseline to follow up. Cumulative distribution functions for
all patients are shown in Figure 4.5 C. The baseline rightward shifts in ΔS/So
(quantified by divergence) are visually evident compared to the healthy standard.
Over the follow up period a further shift in ΔS/So distribution is noticeable for most
patients, indicating increased fibrosis over time.

Discussion
Here we described a small follow up study using non-contrast 2-pt bSSFP
CMR to monitor fibrosis progression in patients on hemodialysis for treatment of
ESRD. The rate of sudden cardiac death increases over time with chronic
hemodialysis [185], indicating that fibrosis may be progressing unchecked,
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without proper measurement or treatment options for these patients. LGE CMR
has become the clinical standard to identify for focal fibrosis and with the addition
of T1 mapping can detect diffuse fibrosis through calculation of the extracellular
volume content [77]. The exclusion from gadolinium enhanced CMR, however,
has severely limited the ability to detect, monitor, and treat fibrosis progression in
patients with ESRD.
While risk of cardiac mortality increases with time on chronic
hemodialysis, we have previously shown that fibrotic burden does not directly
correlate with hemodialysis vintage (Chapter 3). This is evident in the example
participants in this study. At follow up, the patient in Figure 4.3 had received
hemodialysis treatment for 3 years and demonstrated a large fibrotic burden,
compared to over 5 years of treatment for the patient in Figure 4.4, who had a
lower fibrotic burden. This lack of association is consistent with a previous
gadolinium based CMR study, which found no correlation between fibrotic burden
and hemodialysis vintage [58]. So while chronic hemodialysis increases mortality
risk over time, it is necessary to delineate the etiology by determining whether
fibrosis is progressing in the individual patient.
Since cardiac structural [51,56-58] and functional [60,90] alterations are
highly prevalent in the ESRD population, increased hypertrophy and reduced LV
function have been used as surrogate indicators of cardiac fibrosis. While
prognostic in the cardiac and ESRD populations, it is unclear whether these
associate specifically with fibrosis. In fact, fibrosis may precede hypertrophy in
some patients [34]. In this study we showed pervasive progression of fibrosis in
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our patients with ESRD over 1 year (Figure 4.5) without concurrent alterations in
hypertrophy (Figure 4.1), strain (Figure 4.2), or ejection fraction (Table 4.2). It is
surprising that while fibrosis increased, the typical indicators of heart failure
progression—reduced contractility and EF—did not change over this follow up
period. Thus we may be able to distinguish small variations in fibrosis before a
patient has advanced to LV stiffness severe enough to be detected by other
clinical measures.
It is clear that the development of hypertrophy should be considered a
separate disease process from fibrosis progression. Moreover, deterioration of
LV function may only arise after advanced cardiac disease progression, well after
high levels of fibrosis have developed. Thus identification of fibrosis, independent
of structural or functional deficits, could improve prognosis for patients with
ESRD [51].
Patterns of fibrosis have been previously described in hemodialysis
patients [58,59], prior to the ban on gadolinium use. Gadolinium free replication
of these results is now possible and could aid in the understanding of both global
and focal patterns of disease, while monitoring changes over time. Global fibrotic
burden determination may assist in overall cardiac risk stratification [51], however
the visualization of potentially arrhythomogenic fibrotic foci could improve
selection for alternative therapies such as radiofrequency ablation and
implantable cardioverter defibrillators. While nearly 40% of all ESRD deaths are
attributable to arrhythmia and sudden cardiac death, less than 1% of the
hemodialysis population receives implantable defibrillators or resynchronization
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therapies [185]. Noninvasive and safe detection of fibrotic patterns in patients
with ESRD may assist in tapping these underutilized and potentially lifesaving
treatment options to improve the high rates of sudden cardiac death.
While overwhelming increases in ΔS/So and divergence were evident in
this study, a small sample size has limited the ability for us to detect statistically
significant elevations in fibrosis. Measurement of fibrosis progression in patients
on hemodialysis warrants further investigation with a larger sample and multiple
time points. Future analyses should examine the magnitude of change in fibrosis
and correlations to advancing hypertrophy, dilation, or ventricular stiffness in
patients with ESRD. We were also limited by the need for 2 consecutive breath
holds to acquire pairs of images for the 2-pt bSSFP method. Alterations in breath
hold position can introduce misalignment of the myocardium. While we manually
corrected for these shifts, it is possible that erroneous voxels from the blood pool
or pericardium were included in these analyses.
In conclusion, we have shown that patients on hemodialysis for ESRD
nearly ubiquitously developed increased fibrotic burden, even in a short 1 year
period. Fibrosis development is independent of alterations in hypertrophy or
deteriorating contraction or relaxation. The ability to safely monitor patients with
ESRD without the use of gadolinium may assist in more comprehensive risk
stratification, improved treatment selection, and eventually a reduction in cardiac
mortality rates.
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Table 4.1. Baseline Participant Demographics.
Variable
Result
Age (yrs)
54.2 (31.2-79.7)
Male
3 (50)
White
2 (33)
Black/African American
4 (67)
Hemodialysis vintage (yrs)
4.5 (2.0-7.5)
Systolic Blood Pressure (mmHg)
160 (144-182)
Diastolic Blood Pressure (mmHg)
85 (65-98)
Primary Cause of ESRD
Hypertension
3 (50)
Diabetes
2 (33)
Unknown/Unsure
1 (17)
Comorbidities
Hypertension
6 (100)
Diabetes
4 (66)
Numerical variables are presented as mean (range).
Categorical variables are presented as count (%).
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Table 4.2. Clinical Cardiac Measurements.
Variable
Baseline
Follow Up
p
Heart Rate (bpm)
71.8 (59-91)
67.8 (54-86)
0.303
BMI (kg/m2)
31.6 (27.3-39.1)
31.6 (27.3-38.1)
0.934
2
BSA (m )
2.1 (1.8-2.2)
2.1 (1.8-2.3)
0.896
QRS Duration (ms)
90 (76-98)
90 (78-100)
0.681
QTc Interval (ms)
487.5 (444-518)
439.2 (427-456)
0.050*
EDV (mL)
140.6 (95.0-214.0)
131.8 (88.1-185.5) 0.114
ESV (mL)
56.2 (24.9-96.4)
47.7 (18.0-76.2)
0.053
EF (mL)
61.2 (48.6-73.8)
65.9 (52.0-79.6)
0.044*
Cardiac Output (L/min)
6.1 (4.4-8.1)
5.7 (4.5-7.3)
0.419
LV Mass (g)
222.4 (160.9-287.6) 208.4 (163.0-260.1) 0.135
LVMI (g/m2)
110.3 (86.2-130.5)
102.6 (93.2-118.1) 0.157
Septal Thickness (cm)
1.3 (1.1-1.6)
1.2 (1.0-1.5)
0.565
H/R Ratio
0.5 (0.3-0.6)
0.4 (0.3-0.5)
0.138
Data are presented as mean (range). BMI: body mass index, BSA: body surface
area, QTc: corrected QT (standardized to 60 beats per min), EDV: end diastolic
volume, ESV: end systolic volume, EF: ejection fraction, LV: left ventricle, LVMI:
left ventricular mass index (indexed to BSA), H/R ratio: septal thickness/chamber
radius. *p<0.05 was considered significant using a paired t test.
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Figure 4.1. Hypertrophy did not progress over time in patients with ESRD.
Patients with ESRD had elevated (A) LVMI, (B) interventricular septal thickness,
and (C) H/R ratio at baseline but no significant alterations in these measures of
hypertrophy at follow up (all p>0.05). LVMI: left ventricular mass index.
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Figure 4.2. Measures of contraction and relaxation. (A) Circumferential peak
strain and (B) diastolic strain rate show varied, but not significant changes from
baseline to follow up in patients with ESRD. (C) Peak strain and (D) diastolic
strain rate in the longitudinal direction showed no significant changes over time.
These results indicate that LV function did not deteriorate in the follow up period.
All p>0.05.
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Figure 4.3. Representative patient with large increases in fibrosis.
Representative ΔS/So maps at the (A) base, (B) mid ventricle, and (C) apex of a
patient on hemodialysis for ESRD. (D) The bullseye plot revealed low ΔS/So
values across the entire ventricle in this patient at baseline. At the follow up visit,
ΔS/So maps demonstrated elevations in the (E) base and septal regions of the
(F) mid ventricle and (G) apex of the LV. (H) Diffuse elevation was evident across
many slices of the LV, indicating that this patient had developed significant
amounts of fibrosis over the follow up period. Divergence increased by 22.0 AU
in this patient.
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Figure 4.4. Minimal increases in fibrosis over time. At baseline, ΔS/So maps
from this representative patient revealed minor scattered enhancement patterns
in (A) basal, (B) mid ventricular, and (C) apical slices. (D) Average ΔS/So values
remained low across the entire ventricle in this patient. At follow up, myocardial
ΔS/So remained low in the (E) base and (G) apex, with some increased values
developing in the (F) mid ventricle. (H) The corresponding bullseye plot
demonstrated patterns of minor elevations in this patient. Across the 2 study
visits, divergence increased by 3.9 AU, which was the minimal increase in this
group.
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Figure 4.5. Measurements of increased fibrosis in patients with ESRD. (A)
Whole ventricle ΔS/So values increased in all but 1 patient from baseline to follow
up. (B) Divergence values increased in all but 1 patient, indicating a greater
rightward shift in the distribution of ΔS/So values and increased fibrotic burden
over time. (C) Cumulative distribution functions of the healthy simulated standard
(gray), baseline (black), and follow up scans (red). All patients were shifted from
the healthy standard at baseline, corresponding to an increased fibrotic burden
compared to healthy individuals. All but 1 patient demonstrated a greater shift at
follow up, corresponding to further progression of fibrosis.

Copyright © Tori Ann Stromp 2016
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CHAPTER 5: CONCLUSIONS AND PERSPECTIVES

Summary of Key Findings
Contrast-enhanced CMR has become an invaluable tool for myocardial
tissue characterization, advancing our ability to detect and monitor various forms
of fibrosis [64,69-71,74,88]. Unfortunately, the risk of developing nephrogenic
systemic fibrosis has limited the use of gadolinium in individuals with reduced
kidney function [84-86]. This exclusion has thwarted the ability to use our most
powerful CMR techniques in patients with ESRD, who are at high risk of
developing myocardial fibrosis [51,58], arrhythmias, heart failure, and sudden
cardiac death [185]. Without a suitable diagnostic technique, the ability to
understand underlying mechanisms of heart failure in ESRD is hindered, further
limiting the development and testing of appropriate therapeutics. A gadolinium
free and quantitative method for fibrosis detection could overcome these
obstacles and offer a suitable diagnostic and monitoring option with applications
in trials of new therapeutics. The projects in this dissertation have described the
development of a quantitative gadolinium-free CMR technique, subsequent
measurement of cardiac fibrosis in patients with ESRD, and a preliminary study
in longitudinal monitoring of changes in cardiac fibrosis in ESRD patients.
Following previous development in a mouse model of experimentally
induced myocardial infarction [111], we translated 2-pt bSSFP CMR to a cohort
of 47 cardiac patients referred for standard of care LGE CMR plus 10 healthy
age-equivalent controls (Chapter 2). Using high and low MT-weighted cine
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bSSFP image pairs, we were able to extract endogenous contrast from the
alterations in magnetization transfer (MT) arising from extracellular matrix
remodeling. 2-pt bSSFP identified areas of necrosis and edema in acute
myocardial infarction (Figure 2.2), replacement fibrosis in chronic myocardial
infarction (Figure 2.4), and reactive fibrosis in non-ischemic dilated
cardiomyopathy (Figure 2.5). Along with T1 and T2 times, ΔS/So was elevated in
regions of enhancement at LGE compared to myocardium without enhancement
(Figure 2.7). Using gadolinium partition coefficient (GPC) as a contrast based
standard for fibrosis quantification, there was a stronger correlation with ΔS/So
(R=0.82) than with other non-contrast techniques (Figure 2.8). There was strong
agreement in percent of enhanced myocardium (R2 = 0.84) and transmurality of
enhancement (R2 = 0.73) between 2-pt bSSFP and LGE techniques (Figure 2.9).
Agreement was also achieved during subjective assessment by blinded
reviewers of ΔS/So maps compared to LGE images (Figure 2.8), with a few cases
of false positive (Figure 2.10) and false negative (Figure 2.11) identification of
enhancement. Representing a known limitation of LGE CMR, small patterns of
subendocardial signal enhancement were missed in 4 patients using ΔS/So
maps. Time limitations restricted us to the acquisition of only 1 mid ventricular
slice in this cohort, which may have also missed areas of enhancement in some
patients’ hearts.
Extending 2-pt bSSFP to patients on hemodialysis for ESRD, Chapter 3
detailed visual and quantitative fibrosis detection without gadolinium along with
correlations to blood biomarkers that are commonly used to assess ischemia,
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cardiac remodeling, and extracellular matrix turnover. We imaged the entire LV of
29 patients with ESRD and 33 healthy controls of similar age using 2-pt bSSFP
CMR. While we found no differences in ejection fraction nor diastolic strain rate
and only small decreases in global longitudinal strain (Table 3.1, Figure 3.3),
there was widespread LV hypertrophy in the ESRD group (Figure 3.8). Using
cumulative distribution function analysis, we quantified the extent of ΔS/So signal
elevation, to represent a metric of fibrotic burden. Patients with ESRD
demonstrated increased fibrotic burden (divergence=9.8 AU [6.0, 23.6])
compared to controls (4.7 A.U. [1.2, 11.5], p = 0.003). We identified 3 patterns of
fibrosis without gadolinium (Figure 3.6) that were previously described using LGE
[59] in patients with ESRD. Hypertrophy demonstrated only a modest correlation
with fibrosis, while strain did not correlate with fibrosis at all (Figure 3.9). The
existing dogma in the field of heart failure in ESRD patients dictates that
hypertrophy and strain are robust surrogate markers of fibrosis because of the
increased tensile characteristics of fibrotic tissue. Our findings offer compelling
evidence that structural and functional measures are not sensitive to diffuse
extracellular matrix remodeling and interstitial fibrosis. We utilized our capacity to
identify fibrosis to compare fibrotic burden with blood biomarkers of cardiac
stress, ischemia, and extracellular matrix turnover. TnT, FGF23, PTH, and TIMPs
were elevated in patients with ESRD (Table 3.3). The interplay between
hypertrophy and fibrosis was evident in biomarker analysis, as the commonly
employed TnT and FGF23 displayed stronger correlations to hypertrophy than
fibrosis in our cohort. TIMPs, however, were moderately correlated with fibrosis
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but showed no association with hypertrophy. With the ability to distinguish
between hypertrophy and fibrosis, imaging guided biomarkers such as TIMPs
may emerge as fibrosis-specific diagnostic measures and therapeutic targets for
patients with ESRD.
Extension of our findings for the purpose of longitudinal monitoring is
described in Chapter 4 where a preliminary study to detect progression of fibrosis
over time was performed in patients on hemodialysis for ESRD. Patients from the
study in Chapter 3 were asked to return for a follow up exam using 2-pt bSSFP
CMR. Six patients completed the follow-up exam. These patients were
overwhelmingly hypertensive and hypertrophic at baseline (Table 4.1). Over the
follow up period, they demonstrated increased EF (61.2 ± 8.8% to 65.9 ± 10.4%,
p=0.044) but with no corresponding increases in hypertrophy (Table 4.2, Figure
4.1) nor decreases in strain measurements (Figure 4.2). Although no clinically
relevant alterations in structure or function were identified, all but 1 patient
demonstrated an increase in fibrosis over the 1 year follow up period (Figure
4.5). Fibrotic burden and progression may add prognostic value above and
beyond the minimal alterations seen in structure and function to aid in risk
stratification and therapeutic selection for patients on hemodialysis.
Non-contrast CMR techniques for measurement of fibrosis will empower
the investigation of noninvasive biomarkers, molecular targets, and treatment
efficacy in patients with ESRD. Unlike LGE, 2-pt bSSFP can detect both focal
and diffuse disease patterns using a single technique while simultaneously
providing images for clinically important structural and functional measures. We
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are more directly measuring fibrosis in cardiac and kidney patients than the
options currently available to patients with ESRD. We have also challenged the
current dogma and provided evidence that structural and functional alterations
may not be sensitive to the development of interstitial fibrosis which is a critical
substrate for arrhythmias and sudden cardiac death.

Clinical Perspective
Myocardial tissue biopsy has served as the standard for fibrosis detection
via calculation of the collagen volume fraction, primarily in epicardial tissue
samples. Without the use of contrast enhanced CMR, biopsy is the only reliable
alternative for fibrosis measurement in patients with ESRD. Unfortunately, biopsy
is prone to underreporting true fibrotic burden [65], obligates clinicians to
extrapolate the fibrotic content of non-sampled regions, and is invasive and
undesirable for repeated measurements. With 2-pt bSSFP CMR, we have the
ability to observe spatiotemporal changes in the magnitude and pattern of fibrosis
across the entire LV in a way that is not possible with biopsy nor safe with
gadolinium enhanced CMR.
Fibrosis development is a dynamic process that requires complex
molecular cues with unique patterns of activation in order to reorganize existing
extracellular matrix and increase collagen production by fibroblasts [26]. Specific
molecular players in these processes could serve as biomarkers of fibrosis
development and potential treatment targets for attenuation or prevention of
fibrosis. Since hypertrophic and fibrotic remodeling often occur in tandem for
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patients with ESRD, the etiology of cardiac disease development is complex.
Using 2-pt bSSFP we are now able to begin untangling the fibrotic disease
process from structural alterations and investigate the specific underlying
mechanisms and appropriate biomarkers of fibrotic remodeling. For instance,
TnT is widely used to indicate recent myocardial infarction and cardiomyocyte
death, but is often detected in patients with ESRD [189], indicating myocardial
damage from non-ischemic causes. Some have suggested a correlation between
elevated TnT and fibrosis in non-ischemic cardiomyopathy [190] and prognostic
value in ESRD [189,191]. Our results indicate that while TnT correlates with
fibrosis it also correlates with hypertrophy. While it may be prognostic, TnT is
unsuitable as a fibrosis-specific biomarker and may instead reflect a combination
of structural hypertrophy and fibrosis development. Similarly, FGF23 has been
explored as molecular mechanism [53,141,192,193], biomarker [159,194], and
therapeutic target [141,169] of remodeling in patients with ESRD. It has been
extensively correlated with hypertrophy, as we have also shown, yet is also
associated with fibrosis detected by 2-pt bSSFP, rendering FGF 23 unable to
distinguish fibrosis from the associated—but independent—hypertrophic
remodeling process.
The extracellular matrix remodeling process offers alternate molecular
targets that may be more specific to fibrosis development. 2-pt bSSFP allows us
to probe the relationship between MMPs, TIMPs, fibrosis, and heart failure in
ESRD in a safe, noninvasive way. In fact, we have found that TIMPs correlated
with fibrosis but not hypertrophy, which offers promising evidence that these
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peptides may be more specific to fibrosis. Investigations are emerging for the use
of MMP inhibition to attenuate cardiac fibrosis development in animal models of
ESRD [180,195]. 2-pt bSSFP could serve as a method to both interrogate
biomarkers of extracellular matrix turnover and eventually determine the efficacy
of emerging treatments, such as exogenous MMP inhibitors, that are currently
under consideration.

Limitations and Future Opportunities
A few pertinent limitations are present across these studies, which
represent important opportunities for future investigations. As with most CMR
acquisitions, 2-pt bSSFP requires patients to sustain multiple end-expiratory
breath holds. In addition, to achieve maximal resolution we attempt to minimize
voxel size, which can require lengthy breath hold time. Due to need for 2
separate images to complete the 2-pt bSSFP method, the total number of breath
holds and length of time can be limiting for some patients. To begin addressing
breath hold limitations, our lab has investigated the use of 3 dimensional (3D)
cine bSSFP. 3D bSSFP allows for the acquisition of a slab of multiple short axis
slices, spanning a larger portion of the left ventricle during a single breath hold.
This technique has the potential to reduce the total number of breath holds while
maintaining myocardial steady state signal and collecting data across the whole
LV (Figure 5.1). Future investigations could adapt 3D bSSFP to acquire slabs at
flip angles of 5° and 45° for use in 2-pt bSSFP fibrosis imaging with the benefit of
reduced number and total time of breath holds.
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Between the 2 image acquisitions for 2-pt bSSFP, there is a possibility for
patient motion or inconsistent breath holds leading to misalignment of the
myocardium in the image pair. If the myocardium is not aligned, voxels outside of
the myocardium could be included in the analysis of MT and erroneously alter the
measured fibrotic burden. As described in chapters 3 and 4, we manually
registered any image pairs that were not aligned. While this allowed us to
salvage many slices for image analysis, it is possible we introduced other noise
into our analysis. Ideally, a non-contrast imaging technique would achieve
magnetization transfer weighting in a single image, requiring only 1 breath hold
per slice position. Stemming from the need to create better contrast between
endocardial scar and blood pool in LGE images (discussed in Chapter 2), new
techniques are emerging for dark-blood imaging during LGE, using FlowIndependent Dark-blood DeLayed Enhancement (FIDDLE) [196] and T1(Rho)
And Magnetization transfer and INvErsion Recovery (TRAMINER) sequences
[197,198]. In their current uses, these sequences null the blood pool to turn it
black, which allows for enhancement at LGE—especially near the blood pool—to
become more easily visualized after injection of gadolinium. As evident within the
name TRAMINER, these imaging sequences incorporate an MT preparation
scheme that encodes MT within the image. When modified and used without
gadolinium, TRAMINER can extract endogenous contrast via MT weighting
within a single image and therefore single breath hold (Figure 5.2). Studies within
our lab are comparing TRAMINER to LGE in cardiac patients, including patients
with myocardial infarction (Figure 5.2), who are referred for gadolinium based
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CMR. If successful, these preliminary TRAMINER studies could be extended to
non-contrast fibrosis imaging in ESRD patients while lowering the breath hold
burden and eliminating image registration issues that currently exist in our
current techniques. This technique has the added benefit of reducing manual
image correction and post processing time, which are important when evaluating
clinical patients in near real time and for future ambitions to automate image
analysis.
Sub-endocardial scar identification has been a challenge in LGE CMR due
to the low contrast to noise present when a scar is near the bright signal from
blood. This has been the motivation for development of FIDDLE [196] and
TRAMINER [198] described above. Similar limitations exist in 2-pt bSSFP CMR
and were discussed in Chapter 2 and presented in Figure 2.11. Another example
arose in the study from Chapter 3 and is presented in Figure 5.3. This patient
had a history of known myocardial infarction with comorbid hypertension, type 2
diabetes mellitus, and ESRD which requires hemodialysis. Thus, this patient
could not complete gadolinium based CMR to monitor stability of the established
replacement fibrosis nor the presence or progression of additional reactive
fibrosis. Wall thinning is ready apparent in this patient, but it is difficult to define a
fibrotic scar, due to its location near the blood pool. Future development of
magnetization transfer imaging will need to address this issue. One possible
option is to mask the myocardium (as shown in Figure 5.2 B and D) to only
present voxels of interest within the LV. This is limited by the contrast achieved in
anatomical images (e.g. Figure 5.3 A) and accuracy of manual region of interest

116

definition, and removes other anatomical features for reference. While the CMR
field is moving to improve the contrast between myocardium and blood pool in
LGE, MT CMR must go in parallel to limit the uncertainty in sub-endocardial scar
identification. Importantly, similar to extracellular volume (ECV) calculation, MT
CMR has the advantageous ability to image multiple types of fibrosis within 1
imaging technique, as seen in Figure 5.3 B, but without the need for gadolinium.
This is crucial for monitoring patients with prior myocardial infarction who may
develop diffuse reactive fibrosis in remote regions [31,32] and for patients with
multiple risk factors, like those with ESRD, who are at high risk for both ischemic
and non-ischemic fibrosis development [58,59] but who cannot receive
gadolinium.

Additional Future Directions
As 2-pt bSSFP continues to develop, it will be important to assess the
practical clinical utility of this technique and its ability to recapitulate findings from
gadolinium based CMR techniques. In our initial clinical study (Chapter 2) ΔS/So
was highly correlated with gadolinium partition coefficient (R=0.82) and blinded
reviewers with only minimal training were correctly able to identify elevations in
ΔS/So with about 73% agreement to LGE. This was in a sample of patients with
known cardiac disease, demonstrating a variety of fibrosis patterns. It will be
important to determine whether 2-pt bSSFP can be used diagnostically to identify
previously unknown cardiac disease in patients at risk for developing fibrosis. In
the ESRD population, there is a high prevalence of diffuse interstitial fibrosis [51].

117

This pattern is difficult to identify with LGE [63], but can be identified with T1
mapping techniques through ECV calculation [74-76] for patients in which it is
safe to deliver gadolinium. We are currently investigating the ability for 2-pt
bSSFP to identify diffuse fibrosis comparable to ECV in patients with type 2
diabetes with no history of myocardial infarction nor reduced kidney function.
These patients often develop expanded ECM [199] and diffuse myocardial
fibrosis but are still able to receive gadolinium contrast. Importantly, type 2
diabetes is a leading risk factor of ESRD [185] so these patients have similar
medical conditions and comorbidities to many patients with ESRD and may in
fact experience renal complications in the future. While this group is more
homogenous than patients included in Chapter 2, they likely have a less
established cardiac history with less predictable fibrotic burden. We have
scanned 30 patients with type 2 diabetes mellitus and 10 age equivalent healthy
volunteers using 2-pt bSSFP and pre and post-contrast T1 mapping (Figure 5.4).
There are no differences in standard clinical measures of structure and function
between groups but preliminary analysis shows promise for elevated ΔS/So,
native T1, and ECV in the diabetes group. With blinded review, we will now be
able to compare 2-pt bSSFP, native T1 mapping, and ECV quantification across
the entire LV for the de novo identification of diffuse fibrosis. It is important that 2pt bSSFP perform well against current standard contrast techniques both
quantitatively and subjectively if it is to progress toward clinical utility, especially
for the identification of diffuse fibrosis, which is difficult to detect with other CMR
techniques.
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We are also interested in utilizing 2-pt bSSFP to begin understanding the
exceedingly high death rates experienced at the initiation of hemodialysis in
patients with ESRD. There is a severe peak in all cause and cardiac mortality at
month 2 of hemodialysis [185], with a currently unknown cause. Due to the
drastic, hyperphysiologic alterations in hemodynamics [90] we speculate that
early cardiac remodeling and acute fibrosis development might be a risk factor in
this early timeframe. Future studies could utilize 2-pt bSSFP in a large cohort of
ESRD patients who plan to initiate hemodialysis. Imaging before and at multiple
time points within the first year of treatment initiation would offer evidence of
early cardiac fibrosis development—with or without concomitant structure or
function alterations—that could be compared to clinical measures of structure
and function. Cardiac outcomes such as development of arrhythmia, heart
failure, and sudden cardiac death within the first year could be correlated to
fibrosis development to begin to understand the potentially modifiable risk factors
in this critical period for patients beginning hemodialysis.
Blood biomarkers are a promising but complex opportunity for diagnostic
and therapeutic targets in the ESRD population. With limited sample sizes in our
current study (Chapter 3), analyses of blood biomarkers and their correlations
with fibrosis and hypertrophy are modest but promising. Markers of extracellular
matrix remodeling such as MMPs and TIMPs may prove to be more specific to
cardiac fibrosis than the currently employed TnT, FGF23, and PTH which are
confounded by hypertrophy. Larger cohorts of ESRD patients are necessary for
more complex multiple correlation analysis to parcel out the interaction between
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hypertrophy, fibrosis, and individual biomarkers. While MMPs and TIMPs are
imbalanced in patients with ESRD compared to healthy individuals and CKD
patients prior to hemodialysis [148], studies have reported both increases
[146,181,182,200] and decreases [148] in these peptides compared to healthy
controls. This may be a manifestation of the heterogeneous pathophysiology of
cardiac fibrosis in this population. Additional studies are warranted to begin
understanding whether MMP or TIMP concentrations are indicative of either
replacement or reactive fibrosis separately. There is evidence that MMPs and
TIMPs are associated with worsening, but not end stage, heart failure [144].
Serial measurements of these peptides in ESRD patients along with longitudinal
monitoring of cardiac structure, function, and fibrosis by CMR would provide
evidence for the utility of these biomarkers as predictors of heart failure risk and
potential molecular treatment targets for the attenuation of cardiac fibrosis.

Final Remarks
The development of 2-pt bSSFP as a non-contrast CMR technique has
the potential to improve the understanding of heart failure in the context of
ESRD. This safe and noninvasive technique could empower future investigations
for advanced diagnostics and molecular treatment targets for cardiac fibrosis. We
have successfully begun to recapitulate findings from gadolinium based CMR for
quantitative and subjective identification of cardiac fibrosis in patients on
hemodialysis for ESRD. The current challenges in patient burden and post
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processing methods represent vital opportunities for improvements in noncontrast MT techniques that may lead to more clinically applicable CMR tools.
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Figure 5.1. 3D bSSFP image acquisition and signal evolution. (A) Long axis,
4-chamber end diastolic image of the heart with a superimposed schematic of the
slab (solid box) and slice (dashed line) architecture for one representative slab.
(B) Normalized signal intensity waveforms for all six slices in one 3D slab are
shown throughout the entire cardiac cycle. Solid lines represent the middle two
slices (slice 3 and 4) which maintained the best steady state throughout the
entire cardiac cycle.
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Figure 5.2. Fibrosis imaging using a single breath hold magnetization
transfer weighted sequence. (A) A long axis (4-chamber) image acquired with
the clinical standard LGE-CMR in a patient who suffered a myocardial infarction.
Significant enhancement was evident in the apex of the LV. (B) Using a threshold
technique (similar to Chapter 2), myocardial voxels 2 standard deviations above
the average, remote (non-enhanced) myocardial signal were presented in white,
overlayed on all myocardial voxels in gray. (C) A similar long aixs view was
acquired in this patient using a non-contrast, magnetization-transfer weighted
sequence (TRAMINER) in a single breathhold, which revealed significant
elevations in the LV apex. (D) Similar to B, voxels with signal values 2 standard
deviations above the mean were displayed as white with other myocardial voxels
in gray. The image aqcuired without contrast using the TRAMINER technique
showed extremely good spatial agreement with LGE, identifying areas of
edematous and necrotic tissue folowing myocardial infarction. TRAMINER may
emerge as a robust, non-contrast option for tissue characterization without
gadolinium.
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Figure 5.3. Mixed subendocardial scar and diffuse fibrosis in chronic
myocardial infarction. (A) Example bSSFP image from a patient who suffered
a previous myocardial infarction, which was apparent in a large area of severe
myocardial thining (arrow). This patient was also hypertensive, diabetic, and was
on hemodialysis for ESRD and therefore would be excluded from LGE CMR. (B)
It was diffucult to detect a subendocardial pattern of focal scar in the
corresponding ΔS/So map. Contrast between the blood pool and adjacent
elevations in myocardial signal are a limitation of 2-pt bSSFP, as well as other
CMR techniques. The ΔS/So map revealed areas of diffuse enhancement in this
patient that would not be detectable by LGE, however. (C) The T1 map reveals
widespread enhancement, however the myocardium, especially in areas of
thinning, is difficult to resolve. While many CMR techniques share similar
limitations, 2-pt bSSFP may be able to detect both focal and diffuse fibrosis in the
same scanning procedure without the risks associated with gadolinium contrast
agents.
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Figure 5.4. Image acquisitions in a patient with diabetes. (A) ΔS/So map
generated at a mid ventricular slice using 2-pt bSSFP in a patients with type 2
diabetes. This patient demonstrated diffuse enhancement in this and other slices
across the LV. (B) Elevations in T1 are apparent in the native T1 map acquired at
the same slice position. (C) Fifteen minutes post-injection of gadolinium, a postcontrast T1 map was aquired. Maps of pre and post-contrast T1 (B and C) are
compared to calculate GPC and ECV, the predominant method under
investigation for diffuse fibrosis identification.

Copyright © Tori Ann Stromp 2016
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APPENDIX: LIST OF ABBREVIATIONS

2-pt bSSFP two point balanced steady state free precession
BMI

body mass index

bSSFP

balanced steady state free precession

CKD

chronic kidney disease

CMR

cardiac magnetic resonance imaging

CVD

cardiovascular disease

ECG

electrocardiogram

Echo

echocardiography

ECV

extracellular volume (fraction)

EDV

end diastolic volume

EF

ejection fraction

ESRD

end stage renal disease

ESV

end systolic volume

FGF

fibroblast growth factor

FIDDLE

Flow-Independent Dark-blood DeLayed Enhancement

GPC

gadolinium partition coefficient

LGE

late gadolinium enhancement

LVMI

left ventricular mass index

MMP

matrix metalloproteinase

MOLLI

modified Look Locker imaging

MRI

magnetic resonance imaging
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MT

magnetization transfer

PTH

parathyroid hormone

RF

radio frequency

ROI

region of interest

SD

standard deviation

TE

echo time

TIMP

tissue inhibitor of metalloproteinase

TnT

troponin T

TR

repetition time

TRAMINER T1(Rho) And Magnetization transfer and Inversion Recovery
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